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Dedicated to patients suffering from asthma 
 
 
  
ABSTRACT 
This thesis summarizes a series of studies using liquid chromatography coupled to 
mass spectrometry methodologies to quantify metabolites of fatty acids (i.e., oxylipins) and 
histamine in different samples from experimental models and clinical studies with the overall 
aim to define mechanisms and identify biomarkers for improved sub-phenotyping of asthma. 
Asthma is characterized by variable airflow obstruction, hyperresponsiveness and 
chronic inflammation in the airways. The substantial overlap among clinical descriptors has 
resulted in difficulties to establish diagnosis and predict response to treatment. Instead, a shift 
in focus towards identifying specific cellular and molecular mechanisms has emerged, 
aiming to define new treatable traits based on specific cellular and molecular pathways 
(defined as endotypes). Important pathobiological components involve the release of potent 
inflammatory mediators, such as histamine, prostaglandins (PGs) and leukotrienes (LTs), that 
cause bronchoconstriction and airway inflammation.  
A rapid hydrophilic interaction chromatography method failed to quantify the major 
histamine metabolite 1,4-methyl-5-imidazoleacetic acid (tele-MIAA) due to ion suppression 
from inorganic salts present in urine. Ion-pairing chromatography was therefore employed 
and the resulting increase in precision enabled the detection of higher baseline levels of tele-
MIAA in females compared to males (3.0 vs. 2.1 µmol/mmol creatinine, respectively) (Paper 
I). In addition, levels of tele-MIAA reached up to 30 µmol/mmol creatinine in spot urine 
samples from mastocytosis patients. 
Three liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) 
methods quantified 130 oxylipins and were able to define kinetic release and enzymatic 
contribution of mast cell-derived mediators to smooth muscle contraction using isolated and 
intact airways from humans and guinea pigs in vitro. PGD2 levels were elevated 24-hour post 
anti-IgE stimulation of human bronchus, suggesting a prolonged mast cell activation (Paper 
II). Furthermore, exposure to house dust mite (HDM) induced strong release of 
lipoxygenase-derived LTB4, 5,15-DiHETE, 15-HETE and 15-HEDE along with eosinophilic 
infiltration in a C57BL/6 murine model of asthma. Interestingly, high levels of cysteinyl-
leukotrienes (CysLTs) remained unchanged suggesting a different role of CysLTs in mice 
(Paper III). 
Urinary profiles of 11 eicosanoid metabolites in 100 healthy control subjects and 497 
asthmatics defined normal baseline levels and revealed increased concentration of PGs, LTE4 
and isoprostanes with asthma severity. Consensus clustering of 497 asthmatics identified a 
five-cluster model with distinct clinical characteristics, which included two new phenotypes, 
U1 and U5, with low levels of thromboxanes and PGs respectively (Paper IV). At the 12 to 
18-month longitudinal time point for the 302 subjects with severe asthma, z-scored 
eicosanoid concentrations retained the five-cluster profile, despite technical and intra-subject 
variability. 
In conclusion, the developed bioanalytical methods were applied to define levels of 
histamine and eicosanoid metabolites in urine from healthy subjects. In addition, release of 
multiple oxylipins following mast cell-mediated bronchoconstriction and HDM-induced 
airway inflammation in model systems were explored to relate functions to levels of lipid 
mediators. For the first time, grouping of asthmatics according to profiles of eicosanoid 
metabolites in urine was performed and demonstrated sufficient resolution to identify five 
sub-phenotypes of asthma possessing distinct clinical characteristics. The presented 
approaches, for both in vitro and in vivo respiratory research, offer an opportunity to progress 
the development of new treatment options and suggests a panel of PGs, LTE4 and 
isoprostanes to be further validated as diagnostic markers in patients with asthma. 
. 
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1 INTRODUCTION 
Asthma is a chronic inflammatory disease with symptoms of wheeze, cough and 
variable airway obstruction (Fireman, 2003). A substantial proportion of asthmatic patients 
have severe asthma with insufficient control of their symptoms and experience worsening 
events (exacerbations), and consequently have an impaired quality of life. The need for better 
treatment options for this group of patients is evident (Bell and Busse, 2013). Despite the fact 
that some mechanisms in asthma were described early in the 20th century by William Osler 
(1849-1919) the pathogenesis remains unclear. In more specific terms - there is currently an 
incomplete understanding of the molecular mechanisms driving the disease. Consequently, 
there is an unmet need for new biomarkers that better reflect molecular and inflammatory 
mechanisms, and which could also distinguish sub-groups of severe asthmatics. 
 
During airway inflammation, there is a large release of inflammatory mediators. The 
mast cell is one important immune cell in asthma (Bradding and Arthur, 2016; Metcalfe et 
al., 2016), known for its release of potent inflammatory and bronchoconstrictive mediators 
histamine, cysteinyl-leukotrienes (CysLTs) and prostaglandins (PGs). As the released 
mediators bind their specific receptors (H1, CysLT1 and TP) located on the smooth muscle, 
they directly induce constriction of the airways. Following chronic inflammation, the airway 
function can also change and the tissue undergoes cellular remodelling. Herein, oxylipins 
refer to oxygenated polyunsaturated fatty acid (PUFA) metabolites, of which eicosanoids 
have been the most studied to date. The research field of lipidomics is expanding and a large 
number of additional oxygenated lipids have recently been identified as downstream products 
of PUFA metabolism in biological systems (Buczynski et al., 2009; Dumlao et al., 2011). 
The role in the pathogenesis of asthma of a few mediators with pro- or anti-inflammatory 
properties have been studied in more detail, but biochemical function and physiological 
relevance is largely unknown for the majority of oxygenated lipid molecules that can be 
detected today. It therefore remains to be determined if released oxylipins have a mediator 
function or not. Likewise, the baseline excretion levels of many metabolites in healthy human 
urine have not been established.  
 
The focus of this thesis has been to develop advanced bioanalytical methods, using 
liquid chromatography coupled to mass spectrometry (LC-MS), that can quantify mediators 
released by mast cells and other inflammatory cells. The developed LC-MS methods have 
been characterized to accurately determine the urinary marker of released histamine (tele-
MIAA) and arachidonic acid-derived eicosanoids. In addition, a comprehensive panel of 130 
oxylipins was developed to enable assessment of biochemical pathways of cyclooxygenase 
(COX), lipoxygenase (LOX), cytochrome P450 (CYP450) and soluble epoxide hydrolase 
(sEH) enzymes with the corresponding physiological responses of airway smooth muscle 
contractions and airway inflammation.  
 
To demonstrate the utility of these methods, urine samples from clinical studies 
including healthy controls and asthmatic subjects have been evaluated. The large cohorts of 
subjects enabled levels of the major urinary histamine metabolite and eicosanoids to be 
characterized. Furthermore, the comprehensive oxylipin profiling platform was applied to an 
in vivo asthma model in mice to study airway inflammation, and to an in vitro model of mast 
cell mediated bronchoconstriction where changes in oxylipin levels was compared with 
alteration of smooth muscle force following pharmacological treatment. 
 
It is hypothesized that developing quantitative methods for oxylipin profiling and 
urinary tele-MIAA renders it possible to study molecular processes related to the mast cell, 
and perhaps other cells, involved in airway inflammation and bronchoconstriction.   
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2 AIM OF THESIS 
A series of studies were conducted to develop and apply bioanalytical methods that 
determine the levels of the major urinary histamine and eicosanoid metabolites, as well as a 
broad range of oxylipins in multiple samples from different experimental models and in 
clinical studies. The overall aim of the collected efforts was to define mechanisms and 
identify biomarkers for improved sub-phenotyping of asthma. 
 
 
 
In more detail, the methodological aims of this thesis were: 
 
 To develop a simple and repeatable method for quantification of systemic histamine 
turnover in the clinical setting together with use of a sensitive method for 
comprehensive quantification of the major eicosanoid metabolites in human urine 
 
 To set up and demonstrate a translational approach to study oxylipin release from 
isolated and intact human and guinea pig airways following mast cell-mediated 
smooth muscle contractions in vitro 
 
The secondary aims were: 
 
 To describe the oxylipin release profile in bronchoalveolar lavage fluid following 
house dust mite (HDM)-induced airway inflammation in a mice model of asthma and 
from isolated and intact human and guinea pig tissue preparations 
 
 Establish baseline excretion levels in human urine of metabolites of histamine and 
eicosanoids  
 
 Define associations of eicosanoid metabolite levels in urine with clinical traits in 
subjects with asthma  
 
 Use urinary eicosanoid metabolite profiles to sub-phenotype subjects with asthma in 
the clinical observational European U-BIOPRED multicenter study 
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3 BACKGROUND 
3.1 THE NEED FOR BETTER DIAGNOSIS AND TREATMENT IN ASTHMA  
Asthma is commonly described as a heterogeneous and variable respiratory disease 
involving both an acute and a chronic inflammatory response (Papi et al., 2017). The 
biological mechanisms initiating, regulating and terminating (resolving) the airway 
inflammation are not well understood, but are dependent on the interaction between cellular 
and molecular mechanisms. Participating immune cells constitute fundamental parts of both 
the innate and adaptive immune system and exert their coordinated action via signals 
(mediators). Individuals suffering from asthma have variable or persistent airway obstruction 
that give the symptoms of breathlessness, re-occurring wheeze, cough with increased mucus 
production and impaired quality of life.  
 
The aim of current asthma treatment is to: 1) alleviate inflammation and 2) reduce 
smooth muscle constriction. This can be accomplished by the use of inhaled or oral steroids 
and inhaled bronchodilators, such as short or long acting β2-agonists. For the majority of 
individuals with asthma, this treatment strategy stabilizes the symptoms; however, about 5-
10% of asthmatics present frequent exacerbations and lack of control of their symptoms 
despite a high dose of oral corticosteroids. Add-on therapy, such as the use of anti-
leukotrienes or anti-IgE, may alleviate symptoms for some individuals with asthma (Chung 
et al., 2014), but a substantial proportion of patients with severe asthma lack effective 
treatment. Frequent hospital and emergency visits, causing a reduced ability to work, are 
associated with increased societal costs and a reduced quality of life. Consequently, 
individuals with severe, or “difficult-to-treat”, asthma are in great need for improved 
diagnosis and treatment. However, to address this requirement, there is a need to redefine the 
subgroups of asthmatic patients. 
 
The heterogeneous disease asthma is often considered to be an umbrella term 
comprised of several related airway diseases. It is most likely caused by multiple factors. 
Viral infections are believed to be the most common cause for worsening of symptoms and 
exacerbations (Busse et al., 2010; Rosenthal et al., 2010). Viruses are recognized by the toll-
like receptors (TLRs) on antigen presenting cells initiating one type of inflammatory 
response. A genetic susceptibility component is suggested to be an inducing factor at all ages 
(Moffatt et al., 2010). Environmental factors and psychosocial factors, such as stress, are all 
potential triggers of airway obstruction. Allergens are a common environmental trigger 
(Lemanske and Busse, 2010). To add further complexity, a loss of certain microbiome species 
has been associated to negatively influence the immunology of asthma (Heederik and von 
Mutius, 2012). Indeed, asthma is caused by multiple factors and the causes of airway 
inflammation in one particular patient may differ from another. As the underlying 
mechanisms are unclear, one main aim of asthma research is to identify the roots of asthma.  
 
Asthma is classically ascribed as being allergic, with elevated T-helper cells of type 
2. These cells release type 2 cytokines (IL-4, 5 and 13) and recruit eosinophils to the site of 
inflammation. In particular, among severe asthmatics, about 50% have > 2% eosinophils in 
collected sputum samples despite high doses of steroids (Wenzel, 2012; Woodruff et al., 
2009). However, some patients have non-type 2 asthma, where instead, neutrophils 
predominantly infiltrate the lung under the control of type 17 T-helper cells. This type of 
asthma is often associated with a late age of onset (Miranda et al., 2004).  
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3.1.1 New ways to change the clinical definition of asthma 
Our understanding of asthma pathobiology is incomplete. The clinical practice to 
stratify asthmatics into mild-to-moderate, or severe, may be a too simplistic categorization. 
This severity based stratification has been proposed to limit asthma management and 
treatment, and could be one cause of poor clinical outcomes during drug development 
(Pavord et al., 2018).  
 
To address the need for improved diagnosis and treatment of asthma, increased 
research focus has the last decade been directed towards identifying novel sub-phenotypes of 
asthma (Wenzel, 2012). In an early study by Haldar et al. 2008, four different asthma 
phenotypes were described by a clustering approach using clinical variables and sputum 
eosinophils from two cohorts. Later, the Severe Asthma Research Program (SARP) identified 
five asthma phenotypes by another clustering approach, using a reduced set of physiological 
and clinical variables (Moore et al., 2010; Wu et al., 2014). At best, new clinical phenotypes 
may help to explain clinical differences among patients, but identifying specific underlying 
molecular mechanisms would increase the potential to suggest new treatment targets 
(Wenzel, 2016). A research area of increasing interest is therefore to uncover functional and 
pathological mechanisms, referred to as an endotype, or specific mechanisms that respond to 
treatment (Anderson, 2008). 
 
Based upon the concepts mentioned above, the Unbiased BIOmarker Prediction for 
Respiratory Disease outcomes (U-BIOPRED) study was designed with the primary aim of 
performing unbiased molecular data clustering approaches to identify new phenotypes and 
endotypes. To accomplish this, 607 subjects were enrolled, undergoing clinical evaluation 
and collection of multiple biofluid samples for multiple omics-platforms to acquire the most 
comprehensive molecular data set to date. The basic premise of the study was to challenge 
this simplistic description in which asthma has been subdivided by age of onset, type 2 and 
non-type 2 (Wenzel, 2012), and to instead identify detailed molecular descriptors involved 
in asthma. 
 
Clinical cluster analysis of the U-BIOPRED data used a bootstrapping methodology 
based on consensus clustering, which is a different approach to clustering than was used in 
the SARP study and by Haldar et al. Four clinical clusters were identified using only nine 
included clinical variables (Lefaudeux et al., 2016), partly overlapping with previously 
published clinical clusters. Further investigations of the U-BIOPRED cohort have explored 
changes in blood and sputum mRNA transcript, protein profiles as well as in bronchial 
biopsies and brushings. Findings from these studies highlighted molecular signatures related 
to altered epithelial barriers, responsiveness to steroids, type 2 inflammation and activation 
in the IL-6 trans signalling pathway (Bigler et al., 2017; Jevnikar et al., 2018; Kuo et al., 
2017; Takahashi et al., 2018). As the U-BIOPRED project is still in its data analysis phase, 
additional results from multiple omics data integration analysis remain to be reported.  
 
Given the above-mentioned clinical efforts, experimental research models are 
complementary by the use of intervention with specific mechanisms. In this way, important 
features such as airway inflammation and bronchoconstriction can be modulated to further 
increase our understanding. 
3.1.2 In vivo and in vitro models of asthma 
The murine asthma models enable allergen-induced airway inflammation and airway 
hyperresponsiveness to be studied while systematically investigating cellular and molecular 
changes in biological samples from, for example, bronchoalveolar lavage fluid (BALF), lung 
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tissue and biofluids. To study cellular and molecular mechanisms involved in mediating 
allergic airway inflammation, both BALB/c and C57BL/6 mice strains have been used to 
document the involvement of eosinophils, mast cells and neutrophils in this condition. 
Despite the many opportunities with these models, mice lack the branching structure of the 
lung as well as the basic signalling pathways that exist in humans. The serotonin-to-
acetylcholine pathway is the primary mechanism for mediating bronchoconstriction in the 
mice, which distinctly differs from humans where histamine, PGs and LTs are the primary 
mediators (Säfholm et al., 2015). Despite these differences, mice models offer many 
opportunities to characterize specific mechanisms such as comparison of different allergens, 
e.g., alternaria, house dust mite (HDM) and ovalbumin (OVA) (Fuchs and Braun, 2008). 
 
In in vitro experiments, the role of the human epithelial layer in mediating type 2 
inflammation has been studied. The cytokines IL-4, IL-5 and IL-13 are central to the type 2 
mechanism and are frequently upregulated in allergic asthma. Woodruff and colleagues 
demonstrated in patients with mild-to-moderate asthma that using isolated bronchial 
epithelial cells, two subgroups (type 2 high and low) of patients could be identified following 
IL-13 stimulation of cultured cells (Woodruff et al., 2007). The type 2 high group was further 
associated with elevated IL-5 and IL-13 cytokines in their biopsies, AHR, elevated serum 
IgE and eosinophilia, were responsive to inhaled steroids. The cellular and molecular 
evidence for the type 2 mechanism is important, as steroid treatment has proven effective for 
this group of patients and therefore constitutes a fundamental treatment option in asthma. 
 
The events following allergen exposure result in bronchoconstriction and airway 
inflammation. One experimental set up to study the constriction of the airway smooth muscle 
is by use of the organ bath methodology, which enables functional responses to be monitored 
following pharmacological treatment using receptor agonists/antagonists (Säfholm et al., 
2015; Yu et al., 2018). The results from intervening with specific molecular pathways in one 
species can be compared with the same intervention in another species, thereby addressing 
important translational aspects. The guinea pig is the particular species where the lung 
anatomy resembles that of humans (Canning and Chou, 2008). 
3.1.3 Airway physiology 
The upper respiratory system includes the nose and nasal cavity and connects to the 
lower regions where the proximal and distal portions are located. The proximal portion 
consist of the trachea and the main bronchi, while the distal portion hosts the bronchioles and 
alveoli. In human and guinea pigs, the lungs have a clear branching structure where each 
bronchi repeatedly subdivides into two smaller bronchi, Figure 1. During the transport of 
inhaled air from the main bronchi down the bronchial tree to the alveoli, the site where the 
gas exchange occurs, about 23-27 divisions can be observed (Macklem, 1998).  
 
 
 
 
 
 
 
 
 
 
Figure 1. The branching structure of the human 
lung ends with the bronchioles and the alveolar 
sacs where the gas-exchange occurs. 
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The distal airways have an inner diameter of ≤ 2 mm and start at division 8, also 
referred to as the small airways. During obstruction of asthmatic airways, the smooth muscle 
constricts to narrow the bronchi, which can lead to almost complete loss of airflow. In 
particular, among subjects with severe asthma, bronchial wall thickening, edema and 
increased secretion of mucus is frequently observed, leading to reduced efficiency in the 
O2/CO2 gas exchange and a reduction in blood oxygenation. The airway smooth muscle 
surrounding the bronchi is under involuntary control and has attained additional interest in 
asthma research because of its role also to produce many signaling molecules, such as 
cytokines, chemokines and growth factors (Black and Johnson, 2002; Knox et al., 2000). 
 
The epithelial layer is the inner lining of the airways where inhaled air, particles and 
allergens come into contact with the host and therefore constitute an important first defense 
barrier. Furthermore, invading viruses and bacteria are also at this epithelial barrier further 
prevented to penetrate the tissue. Another important function of the epithelial layer is the 
production of pro-inflammatory cytokines IL-13, IL-25, IL-33, TSLP and eotaxin (Holgate, 
2011). These cytokines can recruit eosinophils to amplify inflammatory conditions. In this 
tissue, oxylipins derived from COX, LOX and CYP450 enzyme activity are actively 
produced as well as nitric oxide (NO). 
 
Innate immune cells such as basophils, eosinophils and mast cells are potent effector 
cells and are actively involved in airway inflammation, bronchoconstriction and associated 
with type 2 asthma (Lambrecht and Hammad, 2015). Mast cells are derived from the bone 
marrow and found resident in the skin and within the respiratory tract. Furthermore, 
eosinophils and neutrophils can be recruited to the airways to further enhance inflammation. 
Recently, a lower number of BALF natural killer (NK) cells was observed in severe 
asthmatics (Duvall et al., 2017). The recently identified innate lymphoid cells type II (ILC2) 
cells have shown to substantially contribute to the pathobiology of asthma, but interestingly, 
can be regulated by PGs (Maric et al., 2018). 
3.2 MEDIATORS OF AIRWAY INFLAMMATION AND 
BRONCHOCONSTRICTION 
Maintaining normal physiological conditions requires communication between 
multiple cells and organs. This communication is mediated (signalled) by cell-to-cell 
contacts, released proteins and small molecules. During inflammation, these signaling events 
can be strongly enhanced during cellular activation and follow a kinetic profile that can be 
rapid or slowly changing. The net response can be short, or long acting, and the occurrence 
can be local (autocrine) or peripheral (paracrine).  
 
Important inflammatory signaling pathways are under strict regulation at both the 
cellular and the molecular level. Mast cells are important effector cells in asthma that can be 
activated by either binding of IgE to the high affinity receptor FcεR, binding of cytokines, 
neuropeptides and adenosine, or by changes in osmolarity in the surrounding milieu, Figure 
2.  
Once the activated mast cell degranulates, preformed mediators, such as histamine, 
tryptase, heparin and certain cytokines (e.g., TNFα), are released locally. In addition, de-novo 
synthesis of cytokines and lipid mediators, such as PGs and LTs, lead to their release. 
Histamine, PGs and LTs are well known for their bronchoconstrictive effects and therefore 
the H1, TP and CysLT1 receptors constitute both established and new targets for drug 
intervention. However, the role of the majority of ω3, ω6 and ω9 derived oxylipins are still 
not well understood. These lipid species have therefore also been addressed in this thesis. 
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Figure 2. The mast cell contains potent inflammatory mediators, such as histamine and proteases, 
which are stored in preformed granula. Upon cellular stimulation, degranulation releases these 
constituents to the extracellular environment. Furthermore, activation of cytosolic phospholipase A2 
liberates arachidonic acid from the cellular membrane to de novo synthesize prostaglandins, 
leukotrienes and other eicosanoids. 
3.2.1 Histamine 
Mast cells and basophils contain granules with high amounts of preformed histamine. 
Histamine binds the H1 receptor located on the smooth muscle and in the vasculature to 
induce constriction and increased vascular permeability, respectively. Once histamine is in 
the blood stream, it is rapidly metabolized and transported via the kidneys for excretion. 
Histamine N-methyl-transferase (HMT), diaminoxidase (DAO) and aldehyde dehydrogenase 
(ALDH), are the enzymes that sequentially metabolise histamine into 1-methyl-4-
imidazoleacetic acid (commonly referred to as tele-MIAA), Figure 3. About 75-80% of 
infused histamine is excreted as tele-MIAA in the urine of humans (Granerus et al., 1999b).  
 
In order to accurately determine the release and turnover of histamine, the structural 
analogue pi-MIAA needs to be separated from tele-MIAA. The two molecules differ by the 
methyl-group positioned at the 4th or the 5th carbon position and therefore require careful 
consideration in the choice of separation method, Figure 1, Paper I. Hydrophilic interaction 
liquid chromatography (HILIC) is an attractive option for separation of polar analytes 
because they are better retained than with reversed phase. In reversed phase chromatography, 
low molecular weight, and polar analytes, elute early amd any un-retained sample constituent 
will elute at the same time. In the presence of inorganic salt, which is abundant in biological 
samples, co-elution of inorganic salt can result in marked ion suppression in the electrospray 
source. 
 
 
 
Figure 3: Histamine metabolism via the enzymes HMT, DAO and ALDH produces the stable end-
point metabolite tele-MIAA, which is present in urine. 
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3.2.2 Arachidonic acid and its main metabolites 
Lipids have an essential role in maintaining physiological functions and are 
constituents of every cell membrane. Oxidized lipids also participate in physiological and 
pathophysiological signaling processes and regulate cellular functions such as proliferation, 
migration, apoptosis and metabolism. Arachidonic acid (AA: 5,8,11,14-eicosatetraenoic 
acid) is a 20 carbon ω6 PUFA and is the most well studied lipid species. Its downstream 
metabolites are known to play a key role in mediating inflammatory signals, such as pain, 
vasodilation/contraction or recruitment of inflammatory cells (Dennis and Norris, 2015), 
Figure 4. AA is present in all cells as conjugated via an ester bond at the sn2 position of 
membrane phospholipids.  
 
 
 
Figure 4. Selected eicosanoids and eicosanoid metabolites excreted in urine. Eicosanoids for which 
the chemical structure is shown are quantified in Paper IV. 
The 85kDa cytosolic phospholipase A2 (cPLA2) enzyme liberates AA following 
cellular activation (Leslie, 2004). cPLA2 is found in the endoplasmic reticulum (ER) and the 
nuclear membrane of the cell. Metabolism of AA follows two major pathways, 
cyclooxygenase (COX) and lipoxygenase (LOX). This produces prostaglandins (PGs), 
thromboxanes (TXs), leukotrienes (LTs) and lipoxins (LXs) collectively known as 
eicosanoids (Dahlén et al., 1986). They have several fundamental and important biochemical 
functions, such as regulating renal function, blood pressure, inflammation and host defense. 
After release of AA from the intracellular membrane, COX enzymes can catalyze the 
formation of PGH2 (the main precursor for synthesis of PGs and TXs) through a two-step 
reaction. First, abstraction of hydrogen from AA carbon 13 followed by introduction of 
oxygen at carbon 11 produces a peroxy fatty acid, which by further intramolecular 
rearrangement adds a second oxygen into the molecule producing the cyclic endoperoxide 
PGG2. Further enzymatic reduction generates PGH2, which is the substrate for the various 
PG and TX synthases (Smith et al., 2000). 
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3.2.3 Prostaglandins (PGs) and Thromboxanes (TXs) 
Mast cells almost exclusively express hematopoetic prostaglandin D synthase and 
convert PGH2 into PGD2. PGD2 is therefore considered a marker of mast cell activity (Lewis 
et al., 1982).  With a relatively short half-life, PGD2 is metabolized locally along two 
pathways. The 11-keto-reductase product, 11β-PGF2α, is less biologically active and can 
almost exclusively be detected in blood. However, shortening of the carbon chain length by 
β-oxidation metabolism occurs on the way passing the liver and kidney forming 2,3-dinor-
11β-PGF2α which is referred to as the earlier PGD2 metabolite in urine (Granström et al., 
1982; Roberts and Sweetman, 1985). The second route of PGD2 metabolism goes via carbon 
15-dehydrogenase, delta 13-reductase and both β- and ω-oxidation to form tetranorPGDM, 
which is the most abundant PGD2 metabolite in urine (Song et al., 2008). 
 
Since the identification of prostaglandin E2 (PGE2) and F2α (PGF2α) in human seminal 
plasma in 1963, PGE2  has been attributed both pro- and anti-inflammatory properties, partly 
being tissue dependent (Samuelsson, 1963). PGE2 is also produced from PGH2 but there are 
three alternative synthases that may catalyze the reaction leading to PGE2, microsomal PGE 
synthase -1 and – 2 (mPGES-1, mPGES-2) and cytosolic PGE synthase (cPGES). PGE2 is 
metabolized to tetranorPGEM and excreted in the urine together with primary PGE2 and 
several intermediate metabolites (Hamberg and Samuelsson, 1971), however, substantial 
contribution to urinary levels of primary PGE2 can be attributed to its formation in the kidney 
and prostate. Similarly, the primary PGF-synthase product PGF2α is detected in urine, but is 
known to originate, to some extent, also from the kidney (Frölich et al., 1975). 
 
Inactivation of PGs occurs via oxidation of the secondary alcohol group at C-15 and 
reduction of the double bond at the 13th carbon position. These reactions are catalyzed by 15-
hydroxyprostaglandin dehydrogenase (15-PGDH) and Δl3-reductase. The metabolites formed 
by these reactions, the 15-keto and the 15-keto-13,14-dihydro compounds, have been 
considered a key step in the biological inactivation of prostaglandins since they have much 
lower biologic activities than the parent prostaglandins (Diczfalusy and Alexson, 1990). 
 
Other important PGH2 metabolites include products of prostacyclin synthase (PGI2) 
and thromboxane synthase (TXA2) activity (Hamberg et al., 1975; Moncada et al., 1977). 
PGI2 and TXA2 have opposing physiological functions in the cardiovascular system, where 
PGI2 induces relaxation of smooth muscles and TXA2 contraction and platelet aggregation. 
Similar effects occur in the bronchial smooth muscle. Metabolites of PGI2 include 6-keto-
PGF1α and the 2,3-dinor-6-keto-PGF1α, the former found in plasma and the latter excreted in 
urine (Brash et al., 1983). As the half-life of the instable TXA2 is seconds, the inactive 
product TXB2 is rapidly formed and detectable in circulation, but is further converted to 11-
dehydro- TXB2 and 2,3-dinor- TXB2 excreted in urine (Patrono et al., 1986). 
3.2.4 Leukotrienes (LTs) 
In contrast to COX metabolism of AA, five lipoxygenase activating protein (FLAP) 
binds AA in the cellular nuclear membrane. AA is transferred to co-localized 5-LOX enzyme, 
which produces 5-hydroxyeixosatetraneoic acid (5-HETE) and the unstable product 
leukotriene A4 (LTA4) (Smith, 1989). Depending on cell type, LTA4 hydrolase generates 
LTB4 by the addition of water (Haeggström et al., 2007),  as in neutrophils, while the presence 
of LTC4-synthase, as in mast cells, eosinophils and basophils, enables the incorporation of a 
gluthationyl group producing the first cysteinyl-leukotriene LTC4 (Welsch et al., 1994). 
Following extracellular extraction, LTC4 is rapidly metabolized by γ-glutamyl 
transpeptidase, which cleaves off γ-glutamyl to create LTD4. LTD4 is the most potent 
bronchoconstrictor among the CysLTs. It is about 1000 times more potent than histamine in 
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mediating bronchoconstriction (Dahlén et al., 1980). Finally, LTE4 is formed by dipeptidase 
activity. Because approximately 20% of locally formed LTE4 is rapidly excreted in the urine 
LTE4 is frequently used as a marker of CysLT production (Kumlin et al., 1992; Maltby et al., 
1990). 
3.2.5 Isoprostanes 
In contrast to enzymatically produced oxylipin species, isoprostanes constitute a class 
of non-enzymatically produced oxylipins resulting from increased oxidative stress, they are 
however believed to contribute to the pathobiology of asthma (Milne et al., 2011; Wood et 
al., 2003).  
 
Isoprostanes are formed by free radical induced peroxidation such as by O2
-, H2O2, 
●OH, ozone (O3), commonly termed ROS. Similarly, intracellular NO originates from a 
family of three nitric oxide synthases (NOS) and together with reactive nitrogen species 
(RNS) contribute to the production of oxidized lipids, i.e., isoprostanes (Janssen, 2001). Both 
RNS and ROS have in experimental studies been suggested to mediate important biological 
functions in maintaining homeostasis, and during inflammation by regulating apoptosis, or 
killing invading pathogens (Fadeel et al., 1998; Valko et al., 2007). However, due to the lack 
of specific inhibitors or antagonists, it remains to define the function of isoprostanes in 
humans.  
3.2.6 Oxylipins generated from other PUFAs 
During the last decades, considerable attention has been paid to the role of metabolism 
of PUFAs with different carbon chain lengths, i.e., C18-C22, in inflammatory and infectious 
diseases (Serhan, 2017). Similar to AA, several other PUFAs are stored in the cellular 
membrane and may be metabolized by the incorporation of oxygen at one or more of the 
unsaturated double bonds. Taking all PUFA substrates evaluated in this thesis into account, 
Figure 5, this results in a diverse set of oxygenated lipid metabolite species. Acknowledging 
that membrane phospholipids constitute precursors for oxylipin production, any change in 
cellular membrane composition, i.e., of esterified phospholipids conjugated with PUFAs, 
may have an impact on many pathobiological states (Spector and Yorek, 1985). The main 
PUFA substrates covered in Papers II-IV are highlighted in Figure 5 below.  
 
 
 
Figure 5: Omega-3, -6 and -9 PUFA substrates can undergo enzymatic and non-enzymatic 
metabolism to generate a plethora of oxygenated lipid species. Abbreviations are: soluble epoxide 
hydrolase (sEH), cytochrome P450 (CYP450), lipoxygenase (LOX), cyclooxygenase (COX), reactive 
oxygen species (ROS) and reactive nitrogen species (RNS). For more expanded details regarding 
biosynthetic production of oxylipins see Figure 1, Paper II. 
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The roles of various AA derived oxylipins from the COX enzymatic pathway are most 
well studied. However, as an expanding number of oxidized PUFA metabolites are identified, 
there is an increased demand to characterize their physiological function. In both Paper II 
and III (Figure 1), the detailed pathway figures describes the oxylipins quantified in this 
thesis and the enzymes responsible for their synthesis. One approach to define the role of 
individual oxylipins is by using in vivo and in vitro models where multiple lipid species can 
be quantified and the relative change in concentration of individual lipid species described.  
3.2.7 Enzymes involved in oxylipin production 
During inflammation, the production of specific oxidized lipids and eicosanoids is a 
direct consequence of activated structural and inflammatory cells. These cells sometimes 
share the same enzymes, but expression of enzymes may also be distinctly different, which 
will dictate the set of oxylipins that will be produced in a particular cell, or in the particular 
inflammatory milieu.  
 
Of the two cyclooxygenase enzymes, the COX-1 isoform is constitutively expressed, 
while COX-2 is upregulated during inflammation (Samuelsson et al., 2007). As the COX 
enzymes are largely involved in the production of pro-inflammatory oxylipins, they have 
been frequently used as targets for anti-inflammatory treatment, such as by the non-steroidal 
anti-inflammatory drugs (NSAIDs) aspirin, indomethacin and ibuprofen. Selective inhibition 
of COX-2 has been clinically tested to circumvent the unwanted gastro-intestinal side effects 
of blocking COX-1, which thereby removes the protective function of PGE2. However, due 
to increased cardiac adverse events, selective COX-2 inhibitors have not been as successful 
as anticipated (Mukherjee et al., 2001).  
 
The family of lipoxygenase enzymes (5, 8 and 12/15-LOX) are in principle involved 
in two basic mechanisms, lipid peroxidation and redox-status regulation (Kuhn et al., 2015). 
These enzymes catalyze deoxygenation of the cis-double bonds on PUFAs, which results in 
the introduction of a hydroxyl group. In general, LOX enzymes selectively produce oxidized 
lipids as the S-enantiomers. Four human 12-LOX enzymes have been described, in platelets 
(S-isomer), leukocyte (S-isomer) and epidermis (S- and R-isomers). Furthermore, 5-LOX 
produces 5(S)-HETE. 15-LOX-1 in humans is mainly expressed in eosinophils, monocytes 
and reticulocytes (Haeggström and Funk, 2011) producing 15(S)-HETE, which is the most 
abundant eicosanoid in the human lung (Dahlén et al., 1983; Hamberg et al., 1980; Kumlin 
et al., 1990). A human 15-LOX-2 enzyme also exist and share a high degree of sequence 
identity with mice 8-LOX. 
 
As previously mentioned, 5-LOX is localized in the nuclear membrane and under 
strict control by Ca2+ and ATP (Rådmark et al., 2007) and requires the FLAP protein for 
delivery of arachidonic acid to 5-LOX (Mancini et al., 1993). Pro-inflammatory 5-LOX 
products include LTB4, which is a strong chemoattractant for neutrophils, and CysLTs, which 
mediate bronchoconstriction (Dahlén et al., 1980; Ford-Hutchinson et al., 1980). As a direct 
consequence, montelukast is used for anti-leukotriene treatment in asthma where it 
antagonizes the CysLT1 receptor to reduce bronchoconstriction and airway inflammation 
(Noonan et al., 1998). Another approach to block LT formation is to inhibit FLAP activity 
by the use of MK-886, preventing formation of LTA4. On the other hand, blocking FLAP 
also reduces the ability of 5-LOX to produce the anti-inflammatory mediator lipoxin A4 
(LXA4) and B4 (LXB4). Formation of LXA4 also depend on 15-LOX interaction. LXA4 has 
demonstrated several pro-resolving effects in the lung by promoting phagocytosis of 
apoptotic polymorphonuclear cells (PMNs) and blocking eosinophil trafficking and both 
lower levels of LXA4 and its receptor in the lungs of severe asthmatic patients has been 
reported (Haworth and Levy, 2008). The 8-LOX has to date not been described in humans.  
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A diverse set of LOX products are quantified in Paper II and III and are commonly 
abbreviated by their PUFA origin; such as HODEs (linoleic acid), HOTrEs (α- and γ-
linolenic acid), HDoHEs (docosahexaenoic acid), HETrEs (dihomo-gamma-linolenic acid), 
HETEs (arachidonic acid), HEDEs (11,14-eicosadienoic acid) and HEPEs (eicosapentaenoic 
acid). Their roles in regulating inflammatory events are poorly understood, and therefore, a 
specific aim of this thesis was to assess the presence and abundance of multiple lipoxygenase 
products during airway inflammation in mice and in response to mast cell mediated 
bronchoconstriction in guinea pig and isolated human airways.  
 
The large family of CYP450 enzymes form epoxy-fatty acid compounds from the 
primary substrates LA, AA, EPA and DHA. The epoxy-fatty acid products are involved in 
important physiological functions regulating inflammation and nociception and are generally 
ascribed protective and beneficial properties (Wagner et al., 2017). However, CYP450 
enzymes also produce monohydroxy fatty acids including 19- and 20-HETE. 
 
The soluble epoxide hydrolase (sEH) enzyme hydrolyses epoxides to the 
corresponding vicinal diols to form the DiHOMEs from LA, DiHETEs from EPA, DiHETrEs 
from AA and DiHDPAs from DHA. By the use of selective sEH inhibitors, it has in 
experimental settings been possible to describe potentially important biological functions of 
these epoxy-fatty acids (Guglielmino et al., 2012). Interestingly, in sputum from asthmatics, 
decreased formation of pro-resolving LXA4 has also been associated with increased sEH 
activity, highlighting sEH inhibitors as a new class of compounds of potential benefit in 
asthma treatment (Ono et al., 2014). Elimination of epoxide products is generally considered 
less favorable as those oxylipins have shown anti-inflammatory effects in cardiovascular 
systems by relaxant effects on vascular tone, but also by cellular proliferation and smooth 
muscle migration (Thomson et al., 2012). 
3.2.8 Oxylipin generation by ROS and RNS 
During inflammation, extensive oxidative burst will contribute to the total oxidized 
lipid production. Due to ROS or RNS free radical induced peroxidation occurring, equal 
amounts of the R- and S-enantiomer are produced at any potential chiral centers. To 
determine the contribution of non-enzymatic vs. enzymatically produced oxylipins chiral 
chromatography must be applied to discriminate each enantiomer and the enantiomeric 
excess thus calculated. Chiral chromatography can therefore be essential to elucidate the 
biosynthetic source of production of specific lipid species. For example, 9(S)- and 9(R)-
HETE were shown to be equally produced following lipopolysaccharide and/or zymosan 
stimulated human whole blood while 12(S)- and 15(S)-HETE were the main products 
(Mazaleuskaya et al., 2018). 
3.3 OXYLIPIN PROFILING 
Quantification of PUFA-derived oxylipins and related compounds requires methods 
that are selective and sensitive. For histamine metabolite quantification in urine, selectivity 
is the greatest challenge, while for oxylipins and related eicosanoids sensitivity is more 
important. To achieve high sensitivity, the solid phase extraction technique enables efficient 
clean-up of samples from proteins and inorganic salts, and to concentrate the analytes of 
interest. Following sample clean-up and analyte enrichment, high resolution chromatography 
coupled to high sensitivity mass spectrometry, i.e., a tandem quadrupole mass spectrometry 
(LC-MS/MS) has been exclusively used. This makes it possible to determine the 
concentration of a large number of individual analytes (Yamada et al., 2015; Yang et al., 
2009) from biological fluids. By LC-MS/MS, quantification is performed using multiple 
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reaction monitoring (MRM) transmitting one or more selective fragment ions. In a relatively 
short time frame, hundreds of fragment ion transitions can be monitored. Electrospray 
ionization has been most commonly used to ionize oxylipins and related eicosanoids (Murphy 
et al., 2005). The utility of this analytical technique has been informative in many biological  
applications where oxylipin profiles have been obtained from urine, blood, cerebrospinal 
fluid (CSF) and BALF (Balgoma et al., 2016; Rago and Fu, 2013; Strassburg et al., 2012; 
Wolfer et al., 2015).  
3.4 URINE AS A NON-INVASIVE MATRIX 
Following kidney filtration of blood, the bladder accumulates filtered blood stream 
constituents over longer periods and therefore offers a great opportunity to catch locally 
produced inflammatory mediators (Dahlén and Kumlin, 1998). Local release of PGs, TXs 
and CysLTs can increase tremendously when cells are activated (up to 100-fold). After being 
released in the respiratory tract, they are rapidly taken up by the circulation and metabolized 
systemically, transported by the blood stream and excreted by kidneys. They can therefore 
be detected at elevated levels in the urine. By sampling urine, one for example avoids the risk 
of platelet-derived lipid mediator release due to the interplay between platelets and vascular 
endothelial wall during invasive blood sampling. This has important practical implications in 
the clinical setting, providing a unique opportunity because urine sampling is non-invasive 
and contains enriched biological information. Methods for detection of the mast cell 
mediators histamine, PGD2 and CysLT in urine have been established by immuno-based 
assays as well as by mass spectrometry. Following allergen induced bronchoconstriction the 
subsequent release of PGs and CysLTs is well documented by accurate determination 
whereas markers from the histamine pathway have been studied only occasionally 
(O’Sullivan et al., 1998). For this reason, the major histamine metabolite in urine was 
evaluated in Paper I and an extended panel of 13 eicosanoids from six enzymatic pathways, 
as well as the non-enzymatically produced isoprostanes, were quantified in Paper IV 
(Balgoma et al., 2013).  
 
 14 
4 METHODS 
4.1 GENERAL 
Quantification of small molecular weight compounds in biofluids requires careful 
selection of sample processing methods and detection techniques. Markers of inflammation 
are generally found low at baseline, but can increase 100-fold in the local milieu following 
cellular activation. Furthermore, released mediators also undergo systemic metabolism to 
different degrees during their transport to the blood stream and following clearance by the 
kidneys. Therefore, baseline concentrations of analytes in the various biofluids may span a 
wide dynamic range.  
 
Consequently, low abundant analytes require pre-treatment steps that enrich analyte 
concentration so that sufficient signal can be detected, i.e. above the limit of quantitation 
(LOQ). Regarding markers of mast cell activation, histamine is reported to be found in the 
µmol range in urine (Granerus et al., 1999a), while eicosanoids are found at nmol range 
(Balgoma et al., 2013). The expected range of concentrations of oxylipins in mice BALF is 
only partly described while their presence in human BALF has been reported (Balgoma et 
al., 2016; Larsson et al., 2014; Lundström et al., 2012). The concentrations detected following 
release from isolated lung tissue preparations, when stimulated in vitro, remain to be defined. 
 
Given the challenges above, careful consideration has to be taken with regard to 
sample properties and chemical class of analyte(s), from the start of bioanalytical methods 
development to the final experimental and biological research application, Figure 6. 
 
 
 
Figure 6. The current thesis work has been centered around developing bioanalytical methods for 
quantification of inflammatory mediators in a research setting that involves animal and human models 
as well as clinical studies. 
 
Below follows a description of material and methods used in the different studies 
included in this thesis. A more detailed description is found in each method section in the 
published papers and appended manuscript. 
4.2 A MODEL OF HDM INDUCED AIRWAY INFLAMMATION IN MICE  
In mice models of asthma, ovalbumin (OVA) has commonly been used to establish a 
type 2 inflammatory response in the BALB/c mice strain. Earlier studies using OVA as 
allergen have shown changes in a few oxylipins in BALF. For example, LTB4 and LTC4 have 
been associated with eosinophilic infiltration and mucus secretion. After blocking 5-
lipoxygenase (5-LOX) activity, or 5-LOX activating protein (FLAP), it was possible to 
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reduce this LT production (Henderson et al., 1996). Basal lung levels of a limited panel of 
monohydroxy lipid mediators, such as hydroxyeicosatetraenoic acids (HETEs), have also 
been obtained and compared between rat and BALB/c mice (Sagliani et al., 2013).  
 
In the human population, HDM is a common aeroallergen and many patients with 
asthma are allergic to HDM (Gregory and Lloyd, 2011; Tham et al., 2016). In contrast to 
OVA, HDM triggers inflammation by several mechanisms involving the many complex 
constituents present in HDM (Asokananthan et al., 2002). In our study, HDM was used as 
the allergen. We also wanted to use the C57BL/6 strain, as it offers many possibilities to 
induce genetic modifications. However, in the C57BL/6 mice strain a type 2 inflammatory 
response is more difficult to achieve than in BALB/c and is often skewed towards type 1. 
Thus, to induce allergic inflammation by HDM in C57BL/6 we developed a protocol with 
intense exposure of to HDM during 4 weeks. Of interest, a comprehensive oxylipin profile 
in BALF in response to HDM exposure in the C57BL/6 mice has not been previously 
determined.  
For Paper III, a conditional knock-out mice Igf1rfl/fl was bred in a C57BL/6 enriched 
background for the purpose of studying the conditional deletion of the Insulin Growth Factor 
1 (IGF1) receptor (López et al., 2015). However, no induced knock-outs were used in our 
study and consequently, the phenotype was considered as normal mice. The control mice 
were challenged with PBS and treated were exposed to 20 µL HDM extract for four weeks, 
Figure 7. Animal handling and experiments were approved by the CIBIR Bioethics 
Committee (refs. 03/12, Logroño, Spain) and the Regional Committee of Animal 
Experimentation Ethics (N152/15; Stockholm, Sweden). 
 
 
 
Figure 7: Study design of the murine asthma model in the C57BL/6 mice strain and using house dust 
mite (HDM) as allergen to induce airway inflammation. 
 
Characterisation of airway hyperresponsiveness was evaluated using a FlexiVent™ 
system (Scireq, Montreal, Canada) where mice after the 4 weeks of HDM exposure were 
anesthetized 24-hour after the last HDM challenge. To evaluate the contribution of 3 pro-
inflammatory cytokines and 14 enzymes involved in oxylipin production, their corresponding 
mRNA expression in homogenized whole lung tissue was quantified. Mast cell and 
eosinophil cell infiltration were calculated using isolated lung lobe tissue.  
 
4.3 CLINICAL STUDIES 
Urine samples were collected during a period of 6 and 24 hours in Paper 1 and spot 
urine was collected in the U-BIOPRED study in Paper IV. To further demonstrate the utility 
of the method presented in Paper I, spot urine samples, or hourly collected urines samples, 
were collected in the mastocytosis study (Gülen et al., 2017) and the allergen challenge study 
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(Daham et al., 2014). Ethical permits for studies presented in this thesis were approved by 
the local Swedish ethics committees as follows; Paper I (2009/137, 2009/302-31/3 and 
2009/935-32), Paper IV, the allergen challenge study and the mastocytosis study (2009/959-
31-4 and 2009/1422-32). There was no restriction of diet prior to urine collection. Coffee 
intake was limited to ≤ 2 cups for subjects enrolled in the mastocytosis and allergen challenge 
studies.  
 
Urine samples from the U-BIOPRED study were analysed to determine the 
concentration of urinary eicosanoids in both healthy human subjects and those with mild-to-
moderate (MMA) and severe asthma non-smokers (SAn) and severe asthma smokers, or ex-
smokers, (SAs/ex). Subjects in the U-BIOPRED study were recruited from 16 European 
clinical sites. Number of subjects per group is described in Figure 8 below and inclusion 
criteria followed the ATS/ERS guidelines (Chung et al., 2014).  
 
 
Figure 8. In total, 597 subjects included in U-BIOPRED study were successfully screened to establish 
urinary eicosanoid profiles, Paper IV. 
 
The inclusion criteria for healthy controls was FEV1 ≥ 80%, non-smoking for the past 
12 months and no history of asthma or other respiratory diseases. Subjects in the MMA group 
were non-smokers for the past 12 months and had partial control of their asthma symptoms, 
as defined by GINA guidelines (Bousquet, 2000), following a dose < 500 µg fluticasone 
propionate/day. The SAn group subjects were non-smokers for the past 12 months, had 
uncontrolled symptoms according to GINA, and/or experienced more than two exacerbations 
per year despite ≥ 1000 µg fluticasone propionate/day. All subjects in the HC, MMA and 
SAn groups reported less than 5 total pack-years. The severe asthma smokers/ex-smokers 
(SAs/ex) group followed the same criteria as the SAn subjects, but had a history of smoking 
of > 5 pack-years. Further clinical study details are found in (Shaw et al., 2015).   
 
Extensive clinical evaluation was conducted which included, for example; 
questionnaires, spirometry, measurement of exhaled NO (FENO), blood, sputum and urine 
collection. The median (inter quartile range) FEV1% in the MMA group was 92 (75-100), 67 
(50-85) in SAn and 66 (52-78) in SAs/ex. The overall trend of decreasing lung function 
(FEV1%) with asthma severity is shown Figure 9.  
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Figure 9. Lung function measured as forced expired volume during 1 second (FEV1(%)) 
demonstrated a decline with asthma severity. Healthy control (HC), mild-to-moderate asthma 
(MMA), severe asthma non-smokers (SAn) and severe asthma smokers/ex-smokers (SAs/ex). 
 
A total of 302 severe asthmatics agreed to perform spirometry, blood and sputum 
collection and donate urine at a 12-18 month longitudinal visit. A fewer number of subjects 
underwent bronchoscopy evaluation where bronchial brushings and biopsies were collected. 
All collected subject data (clinical and omics-platform data) in the U-BIOPRED study was 
stored and accessible via the TranSMART data base (http://etriks.org). 
 
4.4 ORGAN BATH METHODOLOGY 
The organ bath methodology is a well-established platform to perform in vitro 
pharmacology using isolated and intact smooth muscle tissues, such as aorta, gastro-intestinal 
and airway tissue. From these preparations major findings, such as the discoveries of PGs, 
LTs, NO and endothelin, have been accomplished (von Euler, 1936; Feldberg et al., 1938; 
Furchgott and Zawadzki, 1980; Palmer et al., 1987). In these preparations, all natural 
signaling routes are present and the cellular structure and function is similar to the in vivo 
situation. Induction of airway smooth muscle constriction can be performed by the addition 
of receptor agonists directly, or indirectly, as by allergic stimulation of the mast cell via 
crosslinking the IgE receptor. Together this enables detailed characterisation of dose-
response curves to study basic mechanisms of bronchoconstriction. For example, this 
experimental system has been able to show that the mast cell stabilizing effect of PGE2 was 
mediated via the EP2 receptor while bronchorelaxant effects were mediated via EP4 (Säfholm 
et al., 2015). 
 
A strength of the organ bath is the possibility to study pharmacological effects in 
different species, such as human bronchus, guinea pig bronchus and trachea as well as mice 
trachea. In these preparations, a simultaneous screening of multiple oxylipins has not been 
reported previously. Developing a workflow to combine data from biochemical pathways 
with that of functional responses may therefore provide novel insights into signalling 
pathways involved in mediating airway smooth muscle responses. The surrounding organ 
bath solvent can be collected and the analytes quantified.  
 
The overall workflow and experiments presented in Paper II are illustrated in Figure 
10 below. In brief, healthy human lung tissue was obtained from individuals undergoing 
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surgical lobectomy at the Karolinska University Hospital. Small airway segments, down to 
bronchi level 16, were isolated and placed over night at 37 °C in culture plate wells containing 
Dulbecco’s modified Eagle medium (DMEM; Gibco, Auckland, NZ) supplemented with 
penicillin streptomycin under sterile conditions on the day before organ bath experiments. 
The use of human tissue was approved by the Stockholm south regional ethical review board 
(ref. no. 2010/181-31/2). 
 
To address translational aspects of bronchoconstriction, male albino guinea pigs were 
also tested in the organ bath setting. Animals were OVA sensitized 28 days prior to organ 
bath experiments by a single intra-peritoneal injection, containing 100 µg. The guinea pigs 
were sacrificed and trachea was isolated and cut into eight intact rings. The Swedish animal 
experimentation ethical review board approved the use guinea pig animals (ref. no. N143/14). 
 
 
Figure 10. A workflow was developed in Paper II to combine physiological and biochemical 
measurements that mimic bronchoconstriction in vivo. Following lobectomy at the Karolinska 
University Hospital, the human bronchus was isolated and mounted in the organ bath. Mast cell 
mediated smooth muscle contraction was induced by anti-IgE and the Newtonian force recorded. 
After 60 min, the surrounding Krebs buffer solvent was withdrawn for SPE processing and subsequent 
oxylipin profiling by LC-MS/MS analysis. 
 
After a period 60 min of tissue stimulation in the organ bath, the surrounding Krebs 
buffer was removed for oxylipin quantification as described in more detail in Paper II. In 
brief, withdrawn Krebs buffer samples were processed by solid phase extraction (SPE) to 
remove interfering salts, proteins and buffer constituents. Following SPE, each dried extract 
was reconstituted in 70 µL of 84% methanol and oxylipins quantified by injecting 7.5 µL of 
each extract into the LC-MS/MS using Methods A-C. Further details of Methods A-C are 
presented in Paper II. 
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4.5 OXYLIPIN AND EICOSANOID ANALYSIS 
The majority of oxylipins are found present at low concentration in biofluids or in 
experimental models. Therefore, samples were cleaned up and concentrated using a solid 
phase extraction (SPE) procedure. This method improved the ability to detect low abundant 
lipid species, while simultaneously decreasing the number of interfering compounds during 
the electrospray ionization process. A cleaner extract also provides for increased 
reproducibility during longer series of sample analysis. 
4.5.1 Extraction and analysis of oxylipins 
In Paper II and III, the same automated extraction protocol was employed using the 
Extrahera robot system (Biotage, Uppsala, Sweden). However, a larger sample volume could 
be extracted from organ bath samples (up to 3.5 mL), while from the mice 800 µL could be 
used. Mice BALF samples were stored five days in -80°C until the day of oxylipin extraction, 
while for organ bath derived samples they were extracted directly following the end of organ 
bath experiment. 
 
In Paper II and III, samples were extracted using 3 mL (3 cc/60mg) Evolute Express 
ABN cartridges (Biotage, Uppsala, Sweden). To each sample, 10 µL of internal standard 
solution was added followed by a 1:1 dilution with an extraction buffer, pH=5.6, 58/42 (v/v) 
of 0.2 M Na2HPO4/0.1 M citric acid hydrate solution. The Extrahera system use a positive 
pressure of N2 gas in the different processing. Evaporation of elution solvent was performed 
using N2 gas (TurboVap LV, Biotage, Uppsala, Sweden). Oxylipin extracts were 
reconstituted in 70 µL methanol/water (6:1, v/v) and filtered by centrifugation using 0.1 µm 
polyvinylidenfluorid membrane spin filters. An overview of the three LC-MS/MS methods 
(A-C) used for Paper II and III is shown in the Figure 11 below. 
 
 
 
Figure 11. Oxylipins were extracted using SPE and the 70 µL extract was injected three times using 
Methods A-C. In Paper II, all methods were used and for Paper III Method A and B. The number of 
analytes included are highlighted for each method. 
4.5.2 Extraction and analysis of urinary eicosanoids 
For quantification of urine eicosanoids in Paper IV, both automated extraction using 
the Extrahera system as well as manual extraction using a vacuum manifold were used. Prior 
to extracting the urine samples, the UV absorbance at 300 nm was measured and the 
withdrawn urine volume was adjusted by an established pool of urine reference material 
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which ensured a more homogenous urine concentration on a sample to sample basis. An 
overview of the three LC-MS/MS methods used for Paper IV is shown in Figure 12 below. 
 
 
 
Figure 12. Urine eicosanoids were analysed in Paper IV by three different LC-separation methods. 
Main prostaglandins, 11-dehydro-TXB2 and isoprostanes were detected by Method D and three 
tautomeric eicosanoids (TXB2, 2,3-dinor-TXB2 and 2,3-dinor-6-keto-PGF1α) by a derivatization step 
included for Method E. LTE4 was quantified by Method F using a separate SPE extraction step.  
 
In principle, the two SPE protocols in Paper IV followed the same basic principles 
as in Paper II and III with the exception samples for determination of urinary LTE4 was 
acidified with 0.1 % aqueous acetic acid prior to SPE loading. In comparison to the positive 
pressure applied by the Extrahera system, the manual SPE extractions using the glass 
manifold used reduced pressure, or gravity, throughout the process.  
4.6 LC-MS AND LC-MS/MS 
4.6.1 Chromatographic separation  
For all papers, liquid chromatography was carried out using an ultra-performance 
liquid chromatography (UPLC) Acquity™ system. In Paper I, ion-pairing chromatography 
was employed using 0.5 mM tridecaflouroheptanoic acid in the aqueous and organic mobile 
phase and histamine metabolite separation performed on a BEH C18 column, 2.1x 100 mm, 
1.7 µm particle size (Waters, MA). In Paper II and III, oxylipin separation was carried out 
using three different methods: general oxygenated lipids (Method A), cysteinyl-leukotrienes 
(Method B) and chiral separation of monohydroxy fatty acids (Method C). Method A and B 
used a BEH C18 2.1x150 mm, 1.7 µm column (Waters, MA) and Method C a Chiral-Pak AD-
RH column, 2.1x150 mm, 5 µm column (Daicel corporation, France). More details regarding 
the different methods employed for urine eicosanoids are found in (Balgoma et al., 2013), 
but included three similar chromatographic methods using the same BEH C18 2.1x150 mm, 
1.7 µm column. 
4.6.2 Mass spectrometric detection 
Mass spectrometry data was collected using the two different mass analyzers from the 
same vendor (Waters, Milford, MA). For Paper I, a full scan function was applied using a 
quadrupole time-of-flight (QTOF Premier™) mass spectrometer and for Paper II-IV a triple 
quadrupole mass analyzer (Xevo TQ and TQ-S™) was operated using multiple reaction 
monitoring (MRM).  
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4.6.3 Quantification of analytes. 
For Paper I, quantification was performed using a calibration curve established by 
the standard addition method, i.e., 1-methyl-4-imidazoleacetic acid spiked into urine in 
increasing concentration. In Paper II-IV, an external calibration curve was created for each 
quantified oxylipin in ≥ 84% methanol. To adjust for variability during sample processing 
and electrospray ionization deuterated standards were added to each sample prior to analysis. 
For quantification of tele-MIAA, either a deuterated structural analog, or amino acid was 
used. For oxylipins, a mix of 42 deuterated structural standards was used. Urinary mediators 
normalized to urinary creatinine 
 
To adjust for fluctuations in urine concentration reported, concentrations of tele-
MIAA and eicosanoids were reported as normalized to mmol/L urine creatinine. In Paper I, 
urine creatinine was determined using a COBAS 6000 C501 clinical chemistry analyser 
(Roch Diagnostics, Indianapolis, USA) or the compensated Jaffe colorimetric assay. In 
Paper IV, urine creatinine was determined using two LC-MS/MS methods (Balgoma et al., 
2013; Fraselle et al., 2015). 
4.7 DATA ANALYSIS 
4.7.1 Univariate analysis 
Univariate statistical methods were applied as appropriate and are described in more 
detail in each paper (I-IV). Urinary tele-MIAA and eicosanoids follow a non-normal 
distribution and were log-transformed prior to analysis of variance (ANOVA). Two-way 
ANOVA was applied for urinary tele-MIAA, controlling for gender and age in Paper I, and 
multiple t-testing in Paper II and III. A Mann-Whitney U-test and Kruskal-Wallis test (one-
way ANOVA) were used for urinary eicosanoids. For longitudinal assessment of SAn and 
SAs/ex participants having urine samples from two time points, a paired t-test was applied 
using the Wilcoxon rank sum test. P-values < 0.05 were considered significant. A false 
discovery rate correction of 5% was applied after multiple testing of oxylipin differences in 
Paper III to adjust for false positives. 
4.7.2 Extreme value analysis 
To discover potential associations between urine eicosanoids with clinical or 
biochemical variables, a selection of objects/subjects having high or low numerical values 
may highlight an important connection between a molecular mechanism and a clinically 
relevant symptom. This selection is referred to as an extreme value analysis wherein the 
selected participants belong to either the high (> 75 percentile) or low (< 25 percentile) 
concentration of a specific analyte. As exemplified using urinary LTE4 in Figure 13, all 
participants having urinary LTE4 concentration above 10.3 ng/mmol and below 3.8 ng/mmol 
creatinine were selected in the first step. In the second step, the corresponding FENO values 
for the selected participants were analysed and statistical significance tested. 
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Figure 13. Selection of U-BIOPRED participants for extreme value analysis based on urinary LTE4 
concentration, i.e., by quartiles (25th and 75th). The selected subjects´ blood eosinophil count is then 
plotted as a scatter plot, or as histogram bar plot. 
4.7.3 Consensus clustering 
Clustering is a class discovery method that attempts to find structure among a group 
of patients or objects. The input data for any class discovery method is based on a larger 
number of variables that reflect measured entities. Typically, this could be mRNA, protein 
or metabolite data. Clustering has been utilized in Paper IV to group participants in the U-
BIOPRED study who have similar urine eicosanoid profiles. To account for differences in 
absolute concentration, numerical ranges and variability of each urine eicosanoid data was 
log2 transformed and subjected to unit variance scaling (i.e., z-scores) or Pareto scaling. The 
Euclidean, and the Pearson correlation, distance measure was calculated and used as separate 
input when searching for similarities between subjects during the clustering computation.  
 
Consensus clustering is a further development of classical clustering by the 
incorporation of bootstrapping during multiple runs of the clustering (Monti et al., 2003). For 
each iteration, a certain percent of the total study participants is left out. The clustering is 
repeated multiple times while testing cluster models of increasing K, i.e., typically K=2 to 
10. For each given K, a consensus matrix is generated wherein the frequency of clustered 
subject pairs is highlighted by a dark blue dot (patient pairs always together), and subject 
pairs that never cluster together by white dot, Figure 5A, Paper IV. A strength of this 
computational approach is the iterative process in which a given partition of subjects is left 
out while the clustering is repeated multiple times, enabling the stability of each model (i.e., 
K1-10) to be evaluated. Measures of how often patient pairs are clustered together is referred 
to as stability and the cumulative distribution function (CDF) plot highlights the stability of 
each K. A flat line in the CDF function plot infers that patient pairs are always clustered 
together. When the pairs do not cluster, the CDF function increases.   
 
To aid stability, or robustness, assessment Senbabaoglu et al. (Senbabaoglu et al., 
2014) proposed a method in which the percent of ambiguously clustered (PAC) pairs is 
calculated to localize optimal K. However, the boundaries (at consensus index 0.1 and 0.9) 
used in the PAC calculation are arbitrary chosen and may negatively compromise the results. 
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Instead, deviation for ideal stability can be identified by finding the model with minimal area. 
The area is calculated above and below a pre-defined line in the CDF plot, drawn orthogonal 
to consensus index 0.5, and can serve as a better estimate of stability (De Meulder et al., 
2018). 
 
 
 
  25 
5 RESULTS DISCUSSION 
5.1 QUANTIFICATION OF MAST CELL DERIVED HISTAMINE  
The initial focus of Paper 1 was to develop a simple and fast LC-MS method for 
determination of the stable end-point metabolite of histamine (tele-MIAA) in urine. Once 
established, this would enable a new sensitive method for detection of increased mast cell 
activation, e.g., after suspected allergic responses, in the clinical setting.  
 
The baseline concentration of tele-MIAA in healthy individuals was determined to be 
2.1 and 3.0 µmol/mmol creatinine, in males and females, respectively. In mastocytosis 
patients up to 10-fold elevation could be observed. Compared to previous standard method 
for urinary tele-MIAA, the improved precision may account for the possibility to detect minor 
shifts in baseline excretion and thereby enabling gender differences to be observed. There 
have been no reports explaining why females and males differ in baseline histamine release 
and this accordingly remains an open question. Furthermore, geographical differences may 
reflect different lifestyles where increased intake of fermented food stuff, like fish, cheese, 
yoghurt and beans, could explain slightly higher excretion of tele-MIAA in the Japanese 
population, Figure 5, Paper I. 
 
The ion-pairing chromatography method was superior to the HILIC method when in-
organic salt induced matrix effects were prominent. Ion suppression negatively affects the 
electrospray process and is most apparent in urine analysis and was clearly compromising 
the initially develop HILIC method, Figure 4, Paper I. In most other biological fluids where 
the aqueous fluid is buffered to maintain constant pH and ionic strength, i.e., plasma and 
cerebrospinal fluid (CSF) ion suppression effect is more equal comparing sample to sample. 
Most likely, this is the reason for why Zhang et al. could establish and validate a HILIC 
method for rapid quantification of acetylcholine, histamine and tele-MIAA in rat CSF 
samples (Zhang et al., 2011).  
 
However, the ion-pairing method demonstrated excellent repeatability (8.4%) across 
a large number of samples from multiple cohorts, Table 3, Paper I. The dilute and inject 
method for urine samples is an attractive preparation method and offered substantial 
simplicity while operating in the lab. The relatively high back pressure, with cycle time peak 
at 14 000 PSI, is demanding for the UPLC and needs to be carefully monitored over time. 
Furthermore, the cycle time of 30 min, sample to sample, is rather inefficient when only one 
analyte is reported. On the other hand, the ion-pairing method can be used to separate more 
than 87 amines present in urine (Waterval et al., 2009). 
5.1.1 Kinetic release of histamine following airway challenge test 
To study the kinetics of the release of histamine, urine samples from a previously 
published allergen-bronchoprovocation study (Daham et al., 2014) have been analysed. The 
data will be compared with the release of eicosanoid metabolites in the same study. To date, 
there are only some preliminary findings compiled, shown in Figure 14. Prior to allergen 
provocation, indicated by arrows in Figure 14, baseline values are in the expected range of 
normal (1-3 µmol/mmol creatinine). Post allergen challenge, urinary tele-MIAA increased 
from the expected baseline of 3 µmol/mmol creatinine up to 11 µmol/mmol creatinine. The 
apparent difference in peak urinary excretion of histamine metabolites between the two 
subjects seemed related to differences in AHR (less release in the most responsive subject), 
a hypothesis that will be tested in the final analysis of the complete profile of released mast 
cell mediators. 
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Figure 14. Time-course of urinary tele-MIAA excretion following allergen challenge, arrows indicate 
time of allergen exposure. Urine samples were then collected in hourly intervals. Grey and black lines 
correspond to placebo or treated (etoricoxib) study arm (blinded groups). 
 
5.1.2 Urinary tele-MIAA is elevated among patients diagnosed with system 
mastocytosis 
In a second study, urine tele-MIAA was determined from healthy controls, patients 
with mild-to-moderate asthma and systemic mastocytosis. Spot urine samples were acquired 
in the morning for assessment of mast cell mediators (Gülen et al., 2017). It could be clarified 
that patients with systemic mastocytosis not only presented elevated serum tryptase and 
urinary PGD2 levels, but also histamine, Figure 15. 
 
 
Figure 15: Urinary concentration of the main histamine metabolite 1-methyl-4-imidazoleacetic acid 
(tele-MIAA) in healthy control subjects, asthmatics and subjects with systemic mastocytosis. Data 
represents average values of two independent time points, with 1-2 hours in between, per subject. 
Group average concentration is highlighted by black line. Mann-Whitney U-test.  
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5.1.3 Identification of the “unknown” 
Finally, the late eluting isobaric compound, i.e., having the same monoisotopic mass, 
that was abbreviated “unknown” in Figure 2a (Paper I) could subsequent to the publication 
be successfully identified as 4-amino-propionic acid (or deamino-histidine), Figure 16. 
Instead of having a methyl-group situated on the imidazole ring, as in the case of pi- or tele-
MIAA, de-amino histidine has one additional carbon incorporated on the short carbon chain. 
The slight increase in carbon chain length probably increased analyte hydrophobicity leading 
to the observed increase in retention time. 
 
 
 
Figure 16. Confirmation of 4-amino-propionic acid (deamino-histidine) retention time (tR=8.54 min) 
in spiked human urine (left) and verification of its unique product ion m/z=123.06 at 10 eV (right). 
5.1.4 Limitations of using tele-MIAA as surrogate marker of histamine release 
There are certain advantages and disadvantages of determining histamine turnover by 
quantifying tele-MIAA in urine. First, urine is a non-invasive matrix and therefore allows for 
repeated sample collections with time. Sample volume is seldom a limitation and instability 
at -20 °C, or even at room temperature, of tele-MIAA in urine has not been reported. 
However, interpretation of urinary concentration levels may be influenced by the intake of 
fermented food stuff, such as cheese, yoghurt and sea food. A high intake of these histamine-
rich food stuff may eventually bias the result. The amount of histamine in certain food items 
has been well described and can therefore be easily avoided. It is notable that the highest 
concentration of urinary tele-MIAA was measured in samples from Japanese subjects, 
Figure 5, Paper I. This could possibly be explained by their different diet, because fermented 
soy and fish products is more common in Asian countries compared to northern Europe. 
Despite the influence from histamine rich food stuff the methodology was able to distinguish 
mastocytosis patients, as those demonstrated up to 10-fold higher concentration of urinary 
tele-MIAA. 
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5.2 DEVELOPMENT AND APPLICATION OF A COMPREHENSIVE OXYLIPIN 
PROFILING PLATFORM  
A comprehensive platform to quantify 130 oxylipins and related lipid mediators was 
developed to enable assessment of molecular mechanisms involved in airway inflammation 
and bronchoconstriction.  
5.2.1 Analytical characterisation of oxylipin method 
The workflow described in Paper II describes three LC-MS/MS methods, which 
together can screen for multiple oxylipins in extracted samples that were redissolved in only 
70 µL. All three methods (A-C), together enabled the quantification of 112 oxylipins and 18 
chiral monohydroxy fatty acids, Figure 17.  
 
 
 
Figure 17. Extracted ion chromatograms of Method A-C. In Method C chiral separation is illustrated 
by extracted ion chromatogram of 5(S)- and 5(R)-HETE. 
 
Measuring multiple analytes in a single analysis is challenging, but we succeeded to 
maintain separation of all analytes having the same molecular mass and to use multiple 
reaction monitoring that uniquely could detect each oxygenated lipid species. In Method A, 
the mobile phases used 0.1% acetic acid in H2O (mobile phase A) and 
acetonitrile:isopropanol (90:10, mobile phase B), but it was unfortunately suboptimal to 
achieve elution of TXB2 as a Gaussian peak. To compensate for its poor peak shape, the peak 
height was used for quantification. The introduction of 84% organic solvent composition in 
the final extract to be injected to the LC-MS/MS system showed however a greater 
improvement in peak shape. 
 
The characterization metrics of the methods demonstrated a lower limit of 
quantification (LLOQ) of 0.016 to 0.7 ng/mL with a linearity of R2>0.98. While the mean 
SPE recovery of 71% was good, for a few oxylipins the extraction was less efficient, such as 
for 5(6)-EpETrE (11%) and tetranorPGEM (31%). Low levels of matrix effects 
(approximately 11%) were observed, and when compared to tissue DMEM media no 
significant difference was seen. 
5.2.2 Organ bath – in vitro pharmacology 
Mast cell stimulation in human segments was induced by adding anti-IgE, and in 
guinea pig by ovalbumin (OVA), to the organ bath followed by recording the change in 
isometric smooth muscle contraction. Figure 2a (Paper II) illustrates the rapid increase in 
contractile force in both human bronchi and guinea pig trachea, reaching Emax within 15 min. 
Before quantifying the parallel release of oxylipins into the surrounding Krebs buffer, a set 
of experiments was conducted to characterize kinetic release, oxylipin stability and freeze-
thaw effects. 
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5.2.3 Application of oxylipin profiling to study mast cell mediated smooth muscle 
contraction 
The kinetic release experiment demonstrated that the major COX products PGD2 and 
PGE2 were released in increased amounts already after 15 min, but reached the highest 
concentration after 60 min, Figure 2c-d (Paper II). In order to obtain a strong signal during 
mass spectrometric detection of oxylipins from the organ bath, the 60 min time point was 
considered as optimal. The constant supply of O2/CO2 into the bath ensures optimal 
physiological conditions for the lung tissue segments, but was highlighted as a main risk of 
oxylipin degradation. In the conducted oxylipin stability experiment, the degradation of 
oxylipins during the time-course of 60 min was individually different with 5(S,R)-HETE 
demonstrating a loss of 92% (Figure 18). Interestingly, substantial degradation was also seen 
for 5 DHA-derived monohydroxy products (HDoHEs) where ≤ 2% of the signal was 
recovered after 60 min (Table S-5, Paper II).  
 
 
 
Figure 18. Degradation of 5(S,R)-HETE, PGD2 and Resolvin D2 following 60 min incubation in the 
organ bath without tissue present. 
 
When samples were collected after 60 min of anti-IgE or OVA induced smooth 
muscle contraction, a strong increase in both COX- and FLAP/5-LOX-derived oxylipins was 
detected (Figure 3, Paper II). Simultaneously, the recorded smooth muscle force (Emax) 
increased from 7 (PBS) to 79% (anti-IgE) in human bronchus preparation. In both species, 
an increase in Emax was observed following the addition of the COX inhibitor indomethacin. 
This functional increase in contraction was followed by a reduction in all prostaglandins 
highlighting the opposing roles PGD2 (constriction) and PGE2 (relaxation).  
 
Other COX products, such as 6-keto-PGF2α, PGF2α and 12-HHTrE were also 
significantly decreased. The latter is produced together with TXB2 by thromboxane A2 
synthase in a 1:1 ratio. TXB2 itself was not detected, which may be due to its short half-life 
in biological systems or to the chromatographic method used. There are no reports on the 
role of 12-HHTrE in mediating smooth muscle contractions. This result was confirmed in 
guinea pig trachea as well. 
 
The addition of a FLAP/5-LOX inhibitor (MK-886) reduced Emax and levels of all 
CysLTs in both species. When the dual combination of COX and FLAP/5-LOX inhibition 
was tested, further reduction in Emax was observed and the corresponding oxylipins 
decreased. From the third injection using Method C, it was possible to define the biosynthetic 
origin of production of 18 monohydroxy fatty acids from LA, AA, and DHA metabolism. 
Interestingly, it was shown that DHA derived 14- and 17-HDoHE, together with 12-HETE 
were solely produced by enzymatic conversion (Table 1, Paper II), whereas 5-, 11 and 15-
HETE, together with 9- and 13-HODE, under these conditions mainly were produced by 
autoxidation, i.e., non-enzymatically. Of interest, under these conditions it was not possible 
 30 
to detect a release of oxylipins with pro-resolving properties, although several were included 
in Method A, such as resolvin D2. 
 
Following 60 min stimulation of human bronchus tissue, the segments were washed 
and transferred to DMEM media and incubated over night at 37 °C. When the surrounding 
tissue media was analysed for oxylipins, a clear signal of elevated PGD2 and its metabolites 
was observed indicating a significant activity of mast cells even after 24 hours (Figure 5, 
Paper II). 
5.2.4 Characterisation of BALF oxylipins after 4 weeks of HDM exposure in mice 
The developed Methods A and B in Paper II were also applied in a mice model of 
asthma to characterize the oxylipin release profiles in BALF following 4 weeks of HDM 
exposure, Figure 7. 24 hours after the last exposure to HDM, airway hyperresponsiveness 
was observed by an increase in lung resistance (RL) and decrease in lung compliance (CL). 
Elevation of Tnf, Il10 and Il13 mRNA transcripts verified that both a type 1 and type 2 
inflammatory response was present. In the C57BL/6 strain, a type 2 inflammatory response 
is usually more difficult to achieve as it is skewed towards type 1. However, the strong 
infiltration of eosinophils into the lungs and the BALF was convincing (Piñeiro-Hermida et 
al., 2017). 
 
In mice BALF, 26 of 59 detectable oxylipins exhibited > 2-fold increase in 
concentration, Table 1, Paper III. In total, 57 oxylipins were detected in control (PBS) mice, 
which provides the largest descriptive signature of oxylipins in an allergic asthma model, 
Figure 4, Paper III. The majority originated from the LOX pathway, but also COX, CYP450 
and sEH products were significantly elevated following HDM exposure.  
 
An attempt was made to relate these elevations to changes at the mRNA level for the 
responsible enzymes, however the RT-qPCR data did not provide such support, Figure 3, 
Paper III. The findings are consistent with the biochemical dogma that substrate availability 
is rate limiting for most eicosanoids rather than downstream enzymes. Furthermore, 
correlating individual oxylipin levels with total number of cells in BALF indicated that the 
number of infiltrating inflammatory cells substantially contributed to the observed increase 
of several oxylipins, such as 5,15-DiHETE, Figure 19. Similar to 5,15-DiHETE, LTB4 
demonstrated a 20-fold increase in HDM exposed animals, but the correlation to total cells 
in BALF was negative.  
 
The most significant signature was the strong elevation of multiple LOX (5-LOX, 
12/15-LOX) products followed by those generated by COX, CYP450 and sEH. In particular, 
the 5-LOX products 5-HETE and LTB4, including its non-enzymatically produced isomers 
6-trans-LTB4 and 6-trans-12-epi-LTB4. Interestingly, PGD2 was significantly elevated, 
while no change in lung mast cell numbers was observed. This is expected, because de novo 
synthesis of PGD2 occurs when mast cells are activated. The source of PGD2 production is 
attributed to mast cells, which possess the necessary PGD-synthase, but other inflammatory 
cells may contribute as well. 
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Figure 19. Spearman rank correlation of total inflammatory cells in mice BALF with that of 5,15-
DiHETE, LTB4 and total CysLT(tot.) concentration in HDM exposed animals. 
 
The finding that the highest levels of all detected oxylipins was CysLT(total) at 
baseline is interesting, and perhaps the unexpected lack of effect following the HDM 
exposure suggest that a different role may exist in mice compared to humans regarding 
CysLTs. Furthermore, correlation of CysLTs to total cells in BALF was similarly negative. 
For example, a LTC4 synthase knock-out mouse demonstrated a role for CysLTs in cutaneous 
vascular permeability and mucin release in the nasal mucosa. This effect was suggested to be 
mediated via LTE4 binding to the GPR99 receptor (Bankova et al., 2016; Maekawa et al., 
2008).  
5.3 CHARACTERISATION OF URINARY EICOSANOIDS IN SUBJECTS WITH 
ASTHMA 
The principle focus of the U-BIOPRED study was to integrate molecular biomarker 
profiles to create a handprint to increase the prediction of treatment efficacy or identifying 
new drug targets. This unbiased omics-approach acquired targeted and untargeted analysis 
of mRNA, protein and metabolite data from multiple biological matrices. By combining the 
collected multivariable data set, it is anticipated to construct a handprint that can sub-group 
asthmatic subjects by their combined molecular profile. Although the urine eicosanoid 
metabolite platform is not an unbiased analytical omics-platform, the strength of the selected 
panel of analytes, Figure 4, is that the analytes reflect mediators with established key roles 
in inflammation, mast cell activation and bronchoconstriction.  
5.3.1 Analytical performance 
Eicosanoids in the laboratory reference material, included in all batches, demonstrated 
a coefficient of variation (CV) between 11.7 to 37.9% in the baseline data set. The 
measurement precision was somewhat better in the longitudinal data set with a CV ranging 
from 2 to 23.7%. Unfortunately, TXB2 and 2,3-dinor-6-keto-PGF2α (the main PGI2 
metabolite) demonstrated a baseline CV > 40% and had to be excluded from the data analysis. 
The eicosanoid data set was collected from multiple batches of sample analysis during a 
three-year period. Longitudinal urine samples were analysed separately from the baseline, 
because they were collected 12-18 months after the baseline time point. For improved 
assessment of intra-individual variability among SA subjects, it may have been more 
appropriate to have analysed the two samples from each subject in pairs. Despite those 
shortcomings, the urine eicosanoids data sets (baseline=597 and longitudinal=302) represent 
the largest comprehensive European data set acquired from subjects with asthma in a cross-
sectional study. 
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5.3.2 Normal baseline excretion of eicosanoid metabolites in HC subjects 
The 100 HC subjects together constitute the largest available cohort of healthy 
individuals defining baseline urinary eicosanoid metabolite concentrations (Figure 2, Paper 
IV). By far the most abundant eicosanoid metabolite in the panel was the major PGE2 
metabolite tetranorPGEM, which was two times higher in males (1510 ng/mmol creatinine) 
compared to females (701 ng/mmol creatinine), confirming previous observed gender 
differences (Daham et al., 2014). In the lung, primary PGE2 is an important smooth muscle 
tone regulator. In patients with aspirin intolerance, maintaining normal airway tone is 
critically dependent on PGE2. It is less clear how useful urinary PGE2 may be as a marker 
reflecting total formation in the lung since the kidney and prostate may produce substantial 
amounts, e.g., radiolabeled infusion of PGE2 recovers less than 4% in urine (Seyberth et al., 
1976). Despite this, we observed 10 ng/mmol creatinine of PGE2 in HC subjects.  
 
Of the two PGD2 metabolites, tetranorPGDM was 3 times more abundant than 2,3-
dinor-11β-PGF2α (188 vs. 46 ng/mmol creatinine respectively), which implies that release of 
PGD2 can be quantified with greater confidence using tetranorPGDM. It also demonstrated 
a CV of 15.3% vs. 23.3% for 2,3-dinor-11β-PGF2α. In the longitudinal samples, 2,3-dinor-
11β-PGF2α was found 3 times lower than in the corresponding subjects’ baseline samples, 
while tetranorPGDM exhibited the same group median. Prostaglandin F2α (PGF2α) binds the 
TP receptor to induce bronchoconstriction in the lung and there exists limited data regarding 
downstream metabolites excreted in urine. In its stable form, primary PGF2α was found at 97 
ng/mmol creatinine in urine from HC subjects. 
 
TXA2 is a potent vasoconstrictor and induces bronchoconstriction also via binding to 
the TP receptor (Manning et al., 1991; Säfholm et al., 2015). It is highly unstable and 
therefore rapidly metabolized into inactive TXB2 (Hamberg et al., 1975). However, the 
kidney is able to produce TXB2 and it may therefore be less useful than its two downstream 
metabolites 11-dehydro-TXB2 and 2,3-dinor-TXB2, which exclusively reflect systemic 
TXA2 production, primarily via platelet activation (Roberts et al., 1977). In the baseline data 
set TXB2 failed to meet QC criteria while its metabolites demonstrated CVs < 38%. Of the 
two TXs metabolites 2,3-dinor-TXB2 were most abundant (48-49 ng/mmol creatinine) while 
11-dehydro-TXB2 were found at 6.8 ng/mmol creatinine, consistent with previous reports 
(Balgoma et al., 2013).  
 
The greatest concentration of the three included isoprostanes was evidenced by 8,12-
iso-iPF2α-VI (392 ng/mmol creatinine) followed by the 2,3-dinor-8-iso-PGF2α (46 ng/mmol 
creatinine). Primary 8-iso-PGF2α is considered to be the gold standard for measuring 
isoprostanes in urine as a marker of oxidative stress and smoking (Montuschi et al., 2000). It 
was found at 23 ng/mmol creatinine. 
 
The least abundant eicosanoid was the end-product of the CysLT pathway LTE4 (3.1 
ng/mmol creatinine). LTC4 and LTD4 were only occasionally detected reflecting their rapid 
metabolism in the lung into LTE4. Apart from CysLTs being known as the most potent 
bronchoconstrictors and powerful inducers of increased vascular permeability, CysLTs are 
chemoattractants for eosinophils. In addition, recent data has demonstrated that inhaled LTE4 
or LTD4 activates the CysLT1 receptor on mast cells causing release of PGD2, which could 
further amplify constriction. This effect was also shown to be completely inhibited by 
montelukast (Lazarinis et al., 2018).  
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5.3.3 Metabolite levels relating to per study protocol recruitment 
As per study protocol evaluation, the most significant observation was the increasing 
concentration of LTE4 with asthma severity (p<0.0001), followed by the two PGD2 
metabolites and 11-dehydro-TXB2, which were increased in SA, Figure 20. Elevated levels 
of LTs and PGs in asthma have been well documented previously, but for the first time, in a 
large cohort of subjects, the excreted levels can be directly compared with disease severity. 
For the remaining eicosanoids, smaller shifts were observed when comparing HC vs. MMA, 
or MMA vs. SAn or SAs/ex (Figure 3, Table S2, Paper IV). Notably, the somewhat large 
intra-group variability for individual eicosanoids most likely reflects that spot urine samples 
contain a snap-shot of the total systemic excretion and is most likely influenced by the current 
degree of inflammatory cell activation, or possibly, how close to an exacerbation the sample 
was collected. 
 
 
Figure 20. Baseline concentration of urine eicosanoid metabolites from cysteinyl-leukotriene (LTE4), 
prostaglandin D2 (tetranorPGDM) and thromboxane (11-dehydro-TXB2) pathways demonstrate 
significantly elevated levels in severe asthma subjects (SAn and SAs/ex). Cohort median indicated 
by flat lines. Kruskal-Wallis test. 
 
5.3.4 Smoking and oxidative stress 
The least abundant isoprostane in urine, 8-iso-PGF2α, demonstrated increased levels 
in the SAn group (27 ng/mmol creatinine), with an even stronger increase (30 ng/mmol 
creatinine) in the smokers group (SAs/ex). The most abundant isoprostane in urine, 8,12-iso-
iPF2α-VI (HC: 392 ng/mmol creatinine) was not different between any groups, despite being 
reported to be upregulated following allergen provocation (Balgoma et al., 2013), while 2,3-
dinor-8-iso-PGF2α was significantly elevated in the smokers group (Table S3, Paper IV).  
5.3.5 Effects of oral corticosteroids (OCS) on urine eicosanoid levels 
The reported use of oral corticosteroids was about 45% in the two SA groups. We 
hypothesized that OCS would not affect the detectable concentration of eicosanoids as has 
previously been published (Gyllfors et al., 2006). Subjects were stratified in the following 
two ways: 1) medical history of being OCS user (Yes vs. NO), and 2) medical history of 
being OCS user, plus detection of prednisolone in urine (Yes vs. NO). The presence of 
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prednisolone was defined by a positive detection of either of prednisone, prednisolone, or 
related hydroxy metabolites of prednisolone, in urine by a specific LC-MS steroid analysis 
method, Table 2, Paper IV. In any of the two comparisons no significant difference was 
observed for 9 of 11 eicosanoids. A significant, but small, decrease was observed for 2,3-
dinor-TXB2 and 8,12-iso-iPF2α-VI using either of the two stratification criteria.  
 
5.3.6 Treatment with anti-IgE 
Interestingly, fewer subjects with extremely high levels of the two PGD2 metabolites 
(2,3-dinor-11β-PGF2α and tetranorPGDM) and LTE4 were observed in SA subjects reported 
to take omalizumab (Xolair), Figure 21 below. This finding strengthens the mechanism that 
removal of free IgE from the systemic circulation stabilises the mast cells, and perhaps other 
cell types as well (Hayashi et al., 2016; Holgate et al., 2005), leading to a reduction in amount 
of allergen stimulation. Verification of this effect is best assessed in follow-up studies with 
an appropriate study design that includes equally balanced groups. However, despite the 
rather weak statistical significance in this analysis, it is clear that fewer subjects were found 
with extremely high urinary levels of prostaglandin D2 metabolites and LTE4.  
 
Figure 21. Urinary concentration of prostaglandin D2 metabolites, 2,3-dinor-11β-PGF2α and 
tetranorPGDM, and LTE4 in severe asthma subjects treated with omalizumab (Xolair: n=62) vs. no 
omalizumab (n=315) in the U-BIOPRED study indicate a potential mast cell stabilizing effect of 
omalizumab. Bar graphs are median (+IQR). Mann-Whitney U-test. 
 
5.3.7 Association between eicosanoids and type 2 inflammation  
T-cells releasing pro-inflammatory cytokines IL-4, IL-5 and IL-13 have been linked 
to increased serum IgE, FENO and eosinophil counts in blood and sputum. More recently, 
serum periostin has been evaluated as a maker of type 2 inflammation, but with less success 
(James et al., 2017; Takayama et al., 2006; Wagener et al., 2015; Woodruff et al., 2007). 
Those characteristics constitute the type 2 inflammatory pathway and have attained great 
focus in treating patients with severe asthma. Correlating urinary LTE4 levels with levels of 
IL-13, periostin, serum IgE, FENO and eosinophil counts for all included study subjects 
highlight scattered data, but statistically significant, exemplified in Figure 22. However, as 
asthma is a variable disease with episodes of worsening of symptoms, i.e., exacerbations, it 
can be speculated that subjects with a more pronounced type 2 signature would also present 
a greater release of eicosanoids.  
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Figure 22. Urinary LTE4 demonstrates a modest increase with: (a) blood eosinophil count (n=583; 
p<0.0001) and (b) sputum eosinophils (%) (n=262; p<0.0001) among subjects in HC, MMA, SAn 
and SAs/ex. Spearman rank correlation (non-parametric). 
 
Therefore, subjects were selected according to the described extreme value approach 
(section 4.8.2), i.e., below the 25th or above the 75th percentile. From the selected panel of 
type 2 markers, LTE4 was significantly associated with blood and sputum eosinophils, FENO, 
IL-13, IgE and serum periostin. Both PGD2 metabolites were linked to elevated blood 
eosinophil counts, sputum eosinophils (2,3-dinor-11β-PGF2α) and IL-13, Figure 4, Paper 
IV. This interesting finding suggests that PGs and CysLTs are important mediators in the 
type 2 inflammatory response and consequently, perturbing those pathways in asthmatics, 
stratified by elevated PGs and CysLTs, could improve treatment efficacy.  
 
Isoprostanes were combined into a composite variable (using z-scores), but were not 
found significantly associated with known markers of type 2 inflammation using the extreme 
value approach. It remains to be evaluated if a significant association exist between 
isoprostanes and type 1 markers of inflammation (i.e., Th17 or Th6 pathways). 
5.3.8 Urinary eicosanoids can distinguish sub-groups of asthma 
Referring to the aim of identifying new molecular sub-phenotypes of asthma, we 
sought to evaluate the strength of clustering the 497 urine eicosanoid profiles from all 
subjects with asthma to distinguish molecular sub-groups. It was hypothesized that there exist 
eicosanoid concentration differences among subjects with asthma that go beyond the 
common cohort classification and which could be used for improved diagnosis. 
 
After evaluation of multiple rounds of unbiased consensus clustering, the final result 
identified a five-cluster model to be further characterised, Figure S1, Paper IV. In this model 
eicosanoid concentration data was log2-transformed and z-scored, and by using the 
Euclidean distance measure as input, the cluster algorithm Partitioning Around the Medoids 
(PAM) was proven successful. Stability of clustered subject pairs throughout the iterative 
bootstrapping process allows deviation from ideal stability to be mathematically estimated 
and visualized, Figure 23a. The objective is to reach a stable horizontal line in the CDF plot. 
Subject pairs, grouped into the five clusters, are visualized in the consensus matrix plot in 
Figure 23b, where dark blue indicates subject pairs who were always clustered together and 
white, which were never clustered together. 
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Figure 23. The CDF plot draws a colored line for each tested cluster model (Kn=2-10) where a moderate 
flat line is highlighted for Kn=5 (a). The consensus matrix for the derived five-cluster model (U1-U5) 
in (b) show patient pairs as dark blue dots if they are always clustered together, while subject pairs 
never clustered together are white.  
 
For Kn=5, the last flat line was achieved having index 0.8, although the length was 
somewhat short. Assessment of clinical and biochemical differences between the obtained 
sub groups demonstrated several significant and important differences summarized in Figure 
24 (Table S4, Paper IV). The mathematically calculated PAC and DIS values provided no 
conclusive evidence to support a selection of model (Kn) and instead the selection approach 
had to rely on the statistical differences of the biochemical and clinical variables describing 
the clusters. Of interest, the median concentration of individual eicosanoids per cluster (U1 
to U5) markedly differed compared to per protocol cohort medians, Figure S2, Paper IV. 
 
In brief, FEV1(%) was < 71% for subjects in cluster U2-U4 and a larger proportion of 
SAn and SAs/ex subjects were clustered here. Subjects in those clusters reported worse 
asthma control (ACQ-5) and quality of life (AQLQ) and reported increased use of oral 
steroids, Figure 24, compared to U1 and U5. 
 
Cluster U3(n=97) was attributed to the largest concentration of PGD2 metabolites and 
all isoprostanes, suggesting oxidative stress to be most prominent among this group of 
subjects. 82% were females, presenting the highest median BMI (30.2) and more frequent 
exacerbations and emergency visits (73%). Interestingly, their elevated CRP also evidenced 
systemic inflammation and their lower levels of serum creatinine may reflect a reduced 
muscle turnover rate, indicative of less physical exercise. This phenotype has been proposed 
to be driven by molecular mechanisms of non-type 2 origin, reduced FENO and elevated 8-
isoprostanes in exhaled breath (Holguin and Fitzpatrick, 2010). Likewise, in cluster U3 FENO 
was low (23.5 ppb), Table 3, Paper IV. Furthermore, PGD2 were most abundant in cluster 
U3 which implies that mast cells play an active role in this phenotype.  
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Figure 24. Urinary eicosanoid metabolites and selected clinical and biochemical variables describing 
the five-cluster model derived from consensus clustering. Values presented as median (IQR). Not 
statistically different (*). 
 
Cluster U2 comprised the largest number of subjects (n=153) with the largest median 
concentration of LTE4 at 8.7 ng/mmol creatinine and with clear type 2 signatures, such as 
elevated FENO (28.5 ppb), sputum eosinophils 4% (IQR; 1-33), blood eosinophils (270 
cells/µL), IL-13 (0.74 pg/mL) and total serum IgE 131 UI/mL (IQR; 52-374).  
 
Cluster U4 was most obstructive (FEV1/FVC=0.63) with median FEV1=63.6%, 
having later onset of age (31 years) and reported the highest use of OCS (IQR; 0-10). 
Surprisingly, only a modest increase in isoprostanes was observed while the interquartile 
range of reported pack-years was the largest (IQR; 0-12.8). As no single eicosanoid 
metabolite in this cluster presented values markedly different from the other, the eicosanoid 
pattern for subjects in U4 was termed “blend”. 
 
 The two remaining clusters U1 and U5 contained 55 and 109 subjects respectively 
with 29 and 27% MMA subjects in each, reflecting a less severe disease state. They 
significantly differed in terms of gender (66% vs. 40% male) and age of onset (29 vs. 16 
years). OCS usage was higher in U5 followed by lower sputum eosinophils 1% (IQR; 0-4). 
In contrast, subjects in U1 presented both elevated FENO (28 vs. 22 ppb) and sputum 
eosinophils 4% (IQR; 1-17). The eicosanoid profiles showed low levels of TXs (cluster U1) 
and PGD2 metabolites (cluster U5).  
5.3.9 Longitudinal 12 to 18-month follow-up  
The variability in clinical symptoms and disease control is a hallmark of asthma. 
Seasonal changes and comorbidities influence the disease state and adjustment of treatment 
dose, or frequency, may be required to maintain optimal control. Using a paired t-test, a 
significant reduction in reversibility from 14.6 to 10.2% (p<0.0001) was seen at 
corresponding longitudinal follow-up time point, but not for any of the other clinical variables 
tested suggesting that subjects remained classified as being severe both at the individual, as 
well as, the group level. 
 38 
The eicosanoid metabolite excretion profiles of the 302 asthmatics is shown for 
tetranorPGDM, LTE4, 2,3-dinor-TXB2 and 8,12-iso-iPF2α-IV in Figure 6A-D (Paper IV). 
For in total 7, out of 11, quantified eicosanoids, including PGE2 and tetranorPGEM, the 
median SAn and SAs/ex concentrations remained the same comparing baseline vs. 
longitudinal time points (±25% of total SA median). An example of intra-individual 
variability is shown for the most abundant isoprostane in urine, 8,12-iso-iPF2α-VI, in Figure 
25 below. A relative comparison of median cluster concentration values clarified that the 
contribution of pathways to the observed cluster levels was preserved, Figure 6E-F, Paper 
IV. Potential reasons for the four eicosanoids exhibiting differences remains to be evaluated. 
 
 
 
Figure 25. Concentration of 8,12-iso-iPF2α-VI in 302 severe asthma subjects at the baseline and 
longitudinal time point highlight a reproducible cluster pattern. Longitudinal data is plotted according 
to the baseline derived five-cluster model. One imputed value in U4 is located outside y-axis range. 
5.4 METHODOLOGICAL CONSIDERATIONS 
In this thesis, quantification of inflammatory mediators in clinical material and 
experimental models has exclusively relied on the use of LC-MS and LC-MS/MS 
technology. It offers some advantages compared to immunological assays, where cross-
linking between molecules and antibodies are used for detection. Immunoassays requires 
development of antibodies with high specificity to avoid unwanted cross-reactivity against 
similar chemical structures or epitopes. While mass spectrometry analyzers offer simplicity 
by keeping sample preparation to a minimum, ionization of intact molecules by the soft 
electrospray ionization (ESI) technique has generally a poor efficiency. Consequently, 
assessing the limit of detection is important for each LC-MS and LC-MS/MS method. 
Despite this limitation, it was possible to report the largest number of oxylipins to be detected 
in mice BALF, and from isolated lung tissue segments, to date.  
 
Although urine is a non-invasive matrix available in larger volumes, the biochemical 
composition, with large amounts of inorganic salt components, is an analytical challenge. 
There are few strategies to handle the large amounts of salt and the great variability that can 
exist between urine samples from patients. In this thesis, in principle three approaches were 
tested for quantification of analytes in urine, of which HILIC was the least suitable. In Paper 
I, we could show that 1:9 diluted urine generated irreproducible standard addition calibration 
curves for tele-MIAA due to severe matrix effects using the developed HILIC method. One 
alternative option to circumvent this could have been to first use SPE to clean up the samples, 
and to remove interfering salt components. On the other hand, that would also extend sample 
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processing time, consumables and laboratory costs. Instead, the final ion-pairing separation 
method utilized a 50-time dilution of urine and provided increased retention and separation 
of structural isomers. While the retention factor increased from k´=3 (HILIC) to k`=24 using 
ion-pairing separation it also minimized the risk co-elution of inorganic salt, as those are not 
retained during reverse phase separation. For the relatively low abundant eicosanoid 
metabolites quantified in Paper IV SPE was necessary to enrich individual eicosanoid 
concentration. Also, the included SPE wash step most likely aided the removal of interfering 
salt components while enabling repeated collection of a purer extract subjected to LC-
MS/MS analysis. 
 
Simplifying sample handling and reducing analysis time can be a bottleneck in 
bioanalysis of large number of samples. The long analysis time in the final ion-pairing 
method decreased throughput, but kept sample handling at a minimum by the simple dilute 
and shoot approach. For future improvements, mobile phase consumption could be reduced 
by switching analytical column size to 1 mm instead of 2.1 mm allowing a reduced flow rate 
(below < 0.2 mL/min) to be used and the total consumed mobile phase volume can be 
estimated to be 60% lower, which would also cause less negative environmental impact.  
 
In Paper II, chromatographic aspects that could improve the operation and speed, 
while reducing solvent use, in Method A-B would be to decrease column length from 150 to 
100 mm. The estimated theoretical decrease in chromatographic resolution would be only 
18%, but may negatively affect separation between stereoisomers, such as 15-epi-LXA4 and 
LXA4, who were not completely baseline separate in Method A. Furthermore, enhanced 
chromatographic resolution in Method C (chiral monohydroxy fatty acids) could be obtained 
by using 3 µm instead of 5 µm particle size columns, and may consequently result in less 
interference between co-eluting 12(S)-HETE (m/z=319.05) and 11(12)-EpETrE (m/z=319.2).  
 
The majority of oxylipin and eicosanoid species are found present in the nanomolar 
range in biological fluids, and consequently following SPE, the reconstituted sample volume 
was kept below 70 µL for both urine, BALF and organ bath samples. In such small volumes, 
not all sample constituents are soluble, leading to fewer number of ions detected. Using a 
higher reconstitution volume could therefore be more efficient and possibly lead to improved 
limit of detection and reproducibility. The electrospray response may also increase if less 
competition exist between analytes during the ionization process (King et al., 2000). A larger 
reconstitution volume would also allow for other methods to be applied on the same extract, 
such as untargeted lipidomics or metabolomics methods (Fauland et al., 2011; Reinke et al., 
2017), or improved quantification of tautomeric structures by derivatization, i.e., TXB2, 2,3-
dinor-TXB2 and 2,3-dinor-6-keto-PGF2α. 
 
The extreme-value analysis was performed using a selection of subjects based on 
concentration quartiles of <25% and >75%. It is possible that using a different cut-off range 
could provide further significance in the proceeding statistical analysis. For example, 
different cut-off values could be tested using an iterative approach and the response variable 
evaluated for improved statistical significance. 
 
Urinary LTE4 was shown to be associated with type 2 inflammatory markers. To 
further increase confidence in these results markers of eosinophil activation, such eosinophil 
cation protein (ECP), eosinophil peroxidase (EPO) or urinary 3-bromotyrosine, could 
confirm if the activated eosinophils were the primary cause of largely elevated LTE4 (Kita, 
2011). 3-bromotyrosine has been suggested as a marker of eosinophil induced peroxidation 
and elevated levels of this halogenated metabolite have shown promising results in at least 
two other studies (Cowan et al., 2015; Wedes et al., 2009). Furthermore, a recent study by 
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Mani (Mani et al., 2016) suggest that 3Br-HPA, may be an even more promising non-invasive 
urinary marker of eosinophil activation.  
 
The relatively few number of sputum samples (222), of the 497 included asthmatics 
in the U-BIOPRED study, is a weakness that negatively influences the power of interpretation 
regarding the five-cluster model, and consequently the low number of sputum samples may 
account for the lack of statistical significance in the corresponding group comparison. 
However, data from other type 2 markers, i.e., IL-13, IgE, FENO and blood eosinophils 
supported the conclusions made. 
 
Class discovery methods have a risk of overfitting, i.e., when larger proportions of 
random noise are introduced in a model. Therefore, splitting up the 497 subjects into a 
training and a validation set is one strategy to increase confidence in cluster analysis. 
However, clustering of training (n=333) and validation (n=164) sets separately reduced the 
number of subjects in the validation set to an extent that no flat line in the consensus CDF 
plot could be obtained. Although the U-BIOPRED study contains the largest cohort of severe 
asthmatics with available urine samples, an increased number of subjects may have provided 
further power in the consensus clustering and improved quality of the cluster interpretations. 
A larger data set also offers other data analysis methods based on machine learning to be 
applied (De Meulder et al., 2018). In this context, it is worth mentioning that unsupervised 
data analysis methods were initially evaluated, such as principle component analysis (PCA) 
(Jackson, 1991) or topological data analysis (TDA) (Lum et al., 2013). From these results it 
was observed that reduction of variance by PCA did not provide any subgroupings apart from 
a minor trend from HC to MMA and SA with great overlap. TDA is an alternative reduction 
method and was able to generate a complex network of subject nodes located in multiple sub-
clusters. When contrasting the network by eicosanoid concentrations, or clinical variables, 
only modest interpretations could be made. No further refinement of the TDA settings was 
evaluated, but is of continued interest to explore, as the method as such, could suggest 
additional separation or subgroupings.  
 
Aspects defining an individual’s lifestyle, such as diet and exercise, will be reflected 
in the metabolic profile of each subject, but controlling for lifestyle factors in clinical studies 
is difficult. However, increasing the number of included subjects may at least increase 
statistical power. Interestingly, in the U-BIOPRED data storage platform TranSMART, 
additional data related to comorbidities, or possible lifestyle factors, is available and should 
be further used to compare specific subgroups. 
 
Finally, urine samples are easy accessible and constitute an attractive non-invasive 
matrix for markers of disease to be detected. However, diurnal variability and comorbidities 
affects the observed concentration of analytes in urine to a various degree and clarifying the 
role of specific dietary components will eventually add value for the future utility of 
mediators quantified in this thesis. Perhaps food stuffs rich in histamine, such as fermented 
food like, cheese, yoghurt and fish serve as a practical example of how lifestyle can influence 
systemic markers. Thus, it can be speculated that reasons for elevated tele-MIAA in the 
Japanese population, compared to US and Sweden, originates from this cause. 
 
Finally, all reported concentrations of mediators in urine were normalised according 
to standard clinical praxis, i.e., to urinary creatinine. However, it is well established in 
athletes that muscle turnover elevates serum creatinine, and consequently, urinary creatinine 
may therefore bias, or skew, the final result. Alternative normalisation methods, such as 
optical density, i.e., specific gravity measurement, may eventually be a more attractive 
alternative.  
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6 CONCLUSIONS 
In the current thesis it was successfully demonstrated that release of inflammatory 
mediators can be quantified using liquid chromatography coupled to mass spectrometry 
analysis of human urine samples, mice BALF and in samples from in vitro organ bath 
experiments. Specifically, it can be concluded that: 
 
 Reduced risk of ion suppression during electrospray ionization is achieved for 
urinary tele-MIAA by ion-pairing chromatography compared to HILIC. (Paper I) 
 
 Females excrete more histamine and less tetranorPGEM than men. (Paper I and IV) 
 
 Inhibition of COX and FLAP/5-LOX in human and guinea pig lung tissue 
preparations results in similar physiological and biochemical responses supporting 
guinea pig as a relevant translational model for further interventional studies. 
(Paper II) 
 
 Significant elevation of PGD2 and its metabolites 24-hour after allergic stimulation 
of human bronchus indicates that mast cells are active longer than expected and that 
it may be related to late phase reactions in the clinical setting. (Paper II) 
 
 Both human and guinea pig isolated airways evidence 15-LOX activity, as 
demonstrated by the production of solely the 14(S)- and 17(S)-HDoHE isomers 
(100% enantiomeric excess). (Paper II) 
 
 HDM induced airway inflammation in C57BL/6 mice is associated with a distinct 
elevation of multiple LOX-derived oxylipins in BALF. (Paper III) 
 
 CysLTs may have a different role and regulation in mice compared to humans. 
(Paper III) 
 
 OCS treatment does not decrease release of eicosanoids in severe asthma, which 
highlights the need for alternative targets for treatment. (Paper IV) 
 
 Female-high BMI phenotype has high levels of isoprostanes and PGD2. (Paper IV) 
 
 Clustering of urine eicosanoid profiles contains sufficient resolution to distinguish 
clinically relevant sub-phenotypes of asthma. (Paper IV) 
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7 GENERAL DISCUSSION 
Airway inflammation is a central pathobiological phenomenon in severe asthma. It 
causes severe impairment of lung function and results in hyperreactivity and variable airway 
obstruction. It is well known that multiple lipid mediators contribute to these events and 
therefore constitute targets for drug treatment. However, since not all asthma patients respond 
to current treatments, increased knowledge about oxylipin profiles among uncontrolled 
patients can allow better diagnosis to be established and perhaps in the future lead to better 
choice of treatment.  
 
As to the presented aims of this thesis, the principle results can be divided into two 
parts, methodological and biological. The methodological achievements were significant in 
Paper I and II, where the greatest effort was centered around the development of LC-MS 
and LC-MS/MS methods, but also to develop an interdisciplinary workflow that enabled 
biochemical and physiological measurements from lung tissue to be combined. The second 
achievement focused on the utility of bioanalytical methods to characterize and describe 
changes in endogenous inflammatory mediators in urine, BALF and organ baths following 
inflammatory cell activation, airway inflammation and bronchoconstriction. The developed 
methods have been utilized in a broad research environment that comprise in vitro and in vivo 
models of human, guinea pig and mice lung tissue. In addition, the utility of non-invasive 
urine samples, from clinical phase I and II studies and a cross-sectional research study, has 
been examined. 
 
Using urinary tele-MIAA as a safety biomarker was successfully demonstrated in a 
clinical trial program monitoring the global systemic histamine turnover. Compared to an 
earlier study where no gender differences were seen, our data support that females excrete 
more histamine than men from three independent clinical studies, but it is unclear what causes 
this difference and if it has clinical relevance (Granerus et al., 1999a). With large increases 
in urinary tele-MIAA following mast cell activation, this gender difference probably has a 
negligible effect. However, limiting a high intake of histamine rich food stuffs is suggested 
to be important during repeated sampling schemes where excreted concentrations approach 
normal baseline levels.  
 
The methods characterised in Paper II were able to quantify 130 different oxylipins 
and included a chiral separation method for monohydroxy fatty acids, Figure 1, Paper II. 
From one single extracted sample, three injections could be made from only 70 µL of 
reconstituted sample extracts. The reversed phase separation methods in Method A had a 17.5 
min cycle time, which is slower than a previously published method adopted in 6 min (Song 
et al., 2013). However, shortening the cycle time generates more co-eluting peaks that can 
lead to inaccurate results. A technical improvement was the use of an automated SPE system 
where positive pressure was used, rather than negative pressure or gravity. Although 
experiments were conducted to demonstrate improved reproducibility by this automation, no 
difference in CV´s was observed. Instead, the total processing time was decreased to 105 
min, as compared to manual extractions taking 130 min. 
 
Previous functional experiments in the organ bath setting have verified the release of 
a few oxylipins, such as TXs, CysLTs and PGs (Dahlén et al., 1983). With our developed 
Method A-C, a large increase in total number of oxylipins (130) was possible to detect. This 
expands the utility. Furthermore, a release of 57 oxylipins from human tissue and 42 from 
guinea pig was observed after mast cell stimulation. In human lung tissue, inhibition of the 
primary COX and FLAP/5-LOX resulted in altered smooth muscle tone while significant 
biochemical PG and LT pathways changed accordingly. The same basic functional and 
biochemical changes were confirmed in the guinea pig trachea. Of interest, the FLAP/5-LOX 
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induced changes of the CYP products EpETrEs and EpOMEs deserve further investigation 
because these epoxides may have an active role in several inflammatory diseases (Wagner et 
al., 2017). Another interesting finding from human bronchi was the elevated PGD2 and its 
metabolites following incubation of bronchi in tissue media for 24 hours, suggesting that 
mast cells have a prolonged activation state. 
 
During inflammation, infiltrating leukocytes exert their actions in part by the release 
of oxidative species. Although isoprostanes are considered markers of free radical induced 
lipid peroxidation/oxidative reactions several of the PUFA-derived oxylipins can be formed 
by autoxidation, wherein equal amounts of the R and S-enantiomer is produced 
(Mazaleuskaya et al., 2018). However, both 5-LOX and 15-LOX enzymes stereo-selectively 
produce hydroxylated lipids with the S-configuration. For the first time, the chirality of organ 
bath released monohydroxy fatty acids from DHA and AA was shown by using Method C 
(Figure 4, Table 1, Paper II). In the same organ bath experiments, 9- and 13-HODE together 
with 5-, 11- and 15-HETE were shown to be products of autoxidation. It is concluded that 
calculated enantiomeric excess increase our understanding of biosynthetic production of 
specific oxylipins and therefore remain to be a fundamental aspect to consider in order to 
define biochemical mechanisms.  
 
In asthma, eosinophilic inflammation is a hallmark of the type 2 inflammatory 
response. The murine BALB/c strain is commonly used to obtain a type 2 inflammatory 
response, while the C57BL/6 strain is more skewed towards type 1. However, our repeated 
intranasal HDM exposure in the C57BL/6 successfully demonstrated infiltration of 
eosinophils, together with elevated Tnf, Il10 and Il13 mRNA transcripts showing that HDM 
triggers both type 1 and a type 2 response. By using this HDM model and applying Method 
A and B, a comprehensive pattern of altered oxylipins described the total presence of 57 
oxylipins in BALF, of which 26 were strongly elevated with HDM exposure. Although a 
release pattern is informative, it is still purely descriptive, because no intervention was added. 
However, to further elucidate the reason for the many elevated oxylipins in BALF, whole 
lung tissue mRNA was investigated to answer whether an elevation of the responsible 
oxylipin producing enzymes could be the cause. We found no such evidence and concluded 
that increased levels of oxylipins must be attributed to either more infiltrating cells, or an 
enhanced level of cellular activation. One weakness in this conclusion is that the 
corresponding proteins in the lung tissue were not quantified.  
 
Furthermore, the observed excessive production of LTB4 is a strong pro-inflammatory 
signal because it promotes neutrophil aggregation, chemotaxis, and superanion oxide 
production. This finding would suggest a prompt oxidative environment and induction of 
isoprostanes. However, of the 5 isoprostanes that could be detected, only 5-iPF2α-VI was 
present. A more detailed assessment of free-radical induced peroxidation could preferably 
have been done by applying chiral separation of monohydroxy fatty acids using Method C, 
but at the time of analysis Method C was not established. 
 
Of interest, further investigative studies in the murine allergic asthma model would 
preferably be to evaluate the effect of specific interventions, such as by inhibiting oxylipin 
producing enzymes or their receptors, or to add oxylipins with anti-inflammatory, or pro-
resolving, properties to study resolution of inflammation. Several oxylipins that are included 
in Method A have pro-resolving properties and may therefore be more likely to be detected 
during a recovery phase where animals are not exposed to HDM. By including such a group 
in parallel, wherein animals are sacrificed at a later time point of for example 3-7 days, an 
altered release profile in BALF may reveal a switch from oxylipins with pro-inflammatory 
properties into those which counteract inflammation, or even promote resolution. Specialized 
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pro-resolving lipid mediators (SPM) are a newly described group of oxylipins capable of 
reducing infiltrating leukocytes, increasing macrophage efferocytosis and thereby actively 
promote a return to tissue homeostasis (Levy and Serhan, 2014). Recent data also suggest 
that this group of oxylipins may in part be involved in failure to resolve airway inflammation 
in asthmatics (Barnig et al., 2018). Although the established platform in Paper II is capable 
of quantifying 6 different SPMs, further development of specific SPM extraction methods, 
together with mass spectrometry detection, is encouraged. Collectively, this would enable 
the later phase of the inflammatory process to be studied in greater detail. 
 
It is increasingly recognized that patients with severe asthma respond insufficiently to 
treatment and have inadequate control of their symptoms. There exists an unmet need to 
identify and develop new clinical and molecular markers of the disease. The use of type 2 
markers has substantially contributed to treat one subgroup of asthmatics, but still, a 
substantial number of subjects present a different endotype, or fall in between type 2 and 
non-type 2. While the call for improved clinical evaluation and molecular characterization of 
subjects with asthma is most apparent, the eicosanoid panel explored in Paper IV constitute 
a significant contribution to molecular sub-phenotyping that may help reshape current 
clinical views and improve diagnosis. 
 
The U-BIOPRED study enabled subjects with mild-to-moderate and severe asthma to 
be extensively evaluated and the release profiles of 11 urine eicosanoid metabolites from five 
enzymatic and one non-enzymatic pathway were defined. Until now, baseline values most 
often originated from smaller studies with fewer subjects included and with often only one 
representative eicosanoid per pathway. In fact, HC subjects in U-BIOPRED provided the first 
large reference cohort of expected normal excretion levels in spot urine and evidenced release 
of LTs to be very low during non-inflamed conditions. With increasing asthma severity, the 
end-product of CysLTs, LTE4, demonstrated the most significant increase with asthma 
severity among the 11 included metabolites, and in some subjects reached urinary levels 50 
times higher than the median baseline value in healthy controls.  
 
The associated link between subjects with high LTE4 (and tetranorPGDM) and high 
levels of type 2 markers further evidence the involvement of mast cells in asthma. LTE4 not 
only promotes eosinophil recruitment, but was recently attributed extended properties as it 
was shown to stimulate mast cells during allergen challenge (Lazarinis et al., 2018). 
 
Corticosteroids down regulate important immune functions and are generally effective 
in patients with eosinophilic asthma. Also, inhaled steroids have been shown to reduce mast 
cell numbers in the airway smooth muscle and epithelium of asthmatics, but not in the 
submucosa (James et al., 2012). An objective measure of adherence to steroid treatment has 
not been previously reported, but was addressed in the U-BIOPRED study. However, only a 
minor difference was observed in two urinary eicosanoid metabolite levels when SA subjects 
were stratified according to reported OCS use, or when a positive detection of urinary 
prednisolone was added as a combined criterion. This extends and confirms previous data 
supporting that most eicosanoid pathways per se are relatively steroid insensitive (Gyllfors 
et al., 2006; O’Shaughnessy et al., 1993). However, reduction in cell numbers with long term 
treatment may indirectly affect eicosanoid metabolite levels. 
 
With respect to the aims of the U-BIOPRED study, unbiased consensus clustering 
demonstrated that urinary eicosanoid metabolites contain sufficient resolution to subdivide 
asthmatics. Furthermore, the clinical and biochemical properties of cluster U2 to U4 partly 
overlapped with previously reported clinical clustering (Haldar et al., 2008; Lefaudeux et al., 
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2016; Wu et al., 2014). Perhaps most clear was the contribution of LTE4, PGD2 metabolites 
and isoprostanes to these clusters.  
 
It has been reported that elevated BMI is associated with reduced levels of FENO 
(Holguin et al., 2013; Komakula et al., 2007; van Veen et al., 2008). Cluster analysis in the 
studies by Haldar et al., SARP and U-BIOPRED have also reported a subgroup consisting of 
females with high BMI, late onset of disease, being associated with reduced FENO and poor 
asthma control, despite reporting use of high doses of oral steroids (Haldar et al., 2008; 
Lefaudeux et al., 2016; Moore et al., 2010). Interestingly, our cluster U3 attained a similar 
description, with the addition of markedly elevated PGD2 metabolites, isoprostanes and LTE4 
together with the highest CRP values. It has also been suggested that this phenotype may 
have a shift in ω6/ω3 diet (Holguin and Fitzpatrick, 2010; Wendell et al., 2014). Even though 
82% of the subjects in our U3 cluster were females, tetranorPGEM was not the eicosanoid 
causing the separation of this cluster. While subjects in cluster U2 presented clear type 2 
cellular and molecular signatures, subjects in cluster U4 had more characteristics of chronic 
obstructive pulmonary disease (COPD) by the low FEV1, FEV1/FVC ratio, latest age of onset, 
reporting the highest dose of OCS and more frequent osteoporosis.  
 
Interestingly, the two clusters having 27 and 29% MMA subjects presented some 
small differences in terms of gender, type 2 signature, age of onset, ACQ-5 and OCS usage. 
Their levels of urinary eicosanoid metabolites were closer to the HC group, but differed by 
lower TXs in U1 and lower PGs in U5. A similar clinical description was presented for two 
of the clusters published by Haldar et al. 
 
In follow-up studies the predictive power of urine eicosanoid metabolites, together 
with cluster significant clinical variables, should be tested to further validate those findings, 
preferably using different class discovery algorithms. The longitudinal follow-up of clinical 
status supported that the recruited severe asthma group were stable. Similarly, the reproduced 
eicosanoid pathway profiles, contributing to the clusters, were in principle maintained in the 
urine, Figure 6E-F, Paper IV. However, median SA concentration of 4 out of 11 eicosanoid 
metabolites was different, of which 3 belonged to the structural family of PGF2α-related 
metabolites. This could best be re-evaluated by a paired analysis of both samples (baseline 
and longitudinal). In addition, it is suggested to further evaluate the observed intra-individual 
variability, which varied depending on eicosanoid metabolite and specific cluster, by taking 
clinical and other biomarkers into consideration. 
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8 FUTURE PERSPECTIVES 
After many years of describing and treating asthma as a single disease, it is now well 
appreciated that patients with asthma present different clinical and molecular signatures 
(Wenzel, 2016). However, it has also been demonstrated that a significant overlap between 
those signatures is prominent. This has led to an emerging need to find better markers of 
disease and treatment response.   
 
In this thesis, in addition to the basic research studies aimed to define oxylipin release 
in tissue preparations and in the chronic allergic asthma model in mice, a substantial effort 
has been made to demonstrate the importance and utility of eicosanoids in asthma. Clearly, 
our data support that eicosanoid production increases with asthma severity and is capable of 
distinguishing clinically relevant subgroups. However, the eicosanoid metabolite signals in 
the clinical setting also demonstrate significant overlap. To address this problem, a next step 
is to characterize the diagnostic accuracy of these metabolite markers in validation 
experiments including repeated measurements over time. Such an experiment would further 
describe the consistency in the excreted eicosanoid patterns and enable the assessment of 
individual variability.  
 
In addition, repeated collection of urine samples would allow improved understanding 
of daily to monthly fluctuations, while variability in clinical symptoms is recorded. 
Furthermore, to address the need for better markers of treatment response, our urinary 
metabolite panel could be further explored when evaluating drug targets during drug 
development. Also, it may be that improved diagnostic accuracy is achieved by the inclusion 
of additional markers, thereby recreating a more complex panel of measured variables of 
different molecular origin, not limited to eicosanoid metabolism.  
 
It was apparent that when comparing the urinary clusters, the concentration 
distribution of eicosanoids metabolites is largely overlapping. If this is due to spot urine 
sampling, or simply to a diverse range of inflammatory cell activation, is unclear. In future 
studies, it would be helpful to include eosinophil activation markers, such as EPX and ECP. 
It is unlikely that a single eicosanoid variable will reach sufficient predictive power to 
distinguish individual patients. Instead, additional molecular and clinical markers will be 
necessary in order to increase selectivity and statistical power. The reality of molecular sub-
phenotyping is that a diverse set of markers will be required in order to deconvolute complex 
heterogeneous diseases and accurately segregate different cellular and molecular processes. 
Indeed, a personalized approach to diagnose and treat asthma is the way towards achieving 
improved asthma control and reduced inflammation in the airways. Large-scale integration 
of clinical and molecular variables (i.e., system medicine) is therefore one way to identify an 
optimal set of predictive variables.  
 
While the utility of the bioanalytical method employed in Paper IV was demonstrated 
in the context of population-based molecular phenotyping, our published workflow (Paper 
II) allows a comprehensive number of inflammatory mediators to be screened in controlled 
experimental models. We applied them in guinea pig and mice models, but the bioanalytical 
methods may of course be used in many other models. Varying sensitisation/exposure 
protocols and sampling schemes will enable anti-inflammatory and pro-resolving hypothesis 
testing before proceeding to clinical evaluation. One such experiment would be to use a LOX 
knock-out in the C57BL/6 mice to characterise the associated cellular and molecular changes. 
Of further interest, is how changes in inflammatory events track with time in HDM induced 
eosinophilic inflammation, such as the progression from an acute to a chronic inflammatory 
state. 
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There are lifestyle factors contributing to clinical asthma that have not been addressed 
in the presented studies. Two such important factors are dietary intake of fatty acids (e.g., ω3 
and ω6) and dietary glycemic load. The dietary ratio of ω6/ω3 has been linked to multiple 
diseases with ongoing chronic inflammation (Calder, 2011; Simopoulos, 2008). With the 
ability to quantify 130 oxylipins, new opportunities exist to investigate dietary interventions 
with greater resolution, thereby enabling new molecular pathways to be associated with 
dietary effects.  
 
One may think that inflammation happens only occasionally, but in fact chronic 
inflammation is increasingly recognised as an underlying, or main, cause of several diseases 
in which PUFAs are suggested to play a role (Minihane et al., 2015). In this thesis, 
inflammation and bronchoconstriction in the airways served as the primary biological events 
under investigation. The properties of the samples selected for the current studies guided the 
development of the bioanalytical methods described herein. However, the utility of the 
methods extends beyond that of urine, BALF or Krebs buffer and may be used for the analysis 
of the same compounds in plasma, sputum, lung tissue biopsies, cell cultures or exhaled 
breath condensates. The latter being another non-invasive sampling technique able to directly 
reflect inflammatory processes in the lung (Sanak et al., 2011). The choice of matrix will 
most likely differ, depending on research question and analyte of interest. 
 
Finally, it is difficult to overstate the importance of research into the fundamental role 
of PUFA-associated biology in the inflammatory process. For decades, research involving 
the study of PUFAs and their many metabolites has provided important knowledge, that for 
example has led to effective anti-inflammatory treatments (e.g., NSAIDs, low dose aspirin, 
anti-leukotrienes and prostacyclin). As chronic inflammation is a growing phenomenon in 
the human population, it has been recognised as one important factor in multiple diseases, 
and as such, the bioanalytical methods developed in this thesis, primarily for inflammation 
in the airways, could have a more widespread area of usefulness in other inflammatory 
diseases. The different innate immune functions we have are the result of an evolutionary 
preserved host defense mechanism that protects us. They are fundamental, but complex, 
biological processes under strict regulation. In view of this, histamine, oxylipins and related 
eicosanoids are control systems of considerable importance. Low molecular analytes are 
exciting entities, but are technically advanced to capture. However, their role and function in 
immunology cannot be emphasized enough and will keep us motivated for continued future 
work. To quote Roy J Sobermans statement published in Journal of Clinical Investigation 
2003: 
 
“…the combination of 20 carbons and four unsaturated double bonds has proved to 
be one of the most flexible molecular combinations yet described and has provided the 
stimulus for over 50 years of intense investigation. As more roles and interactions for 
arachidonic acid products are identified, it is clear that this molecule will remain an integral 
component of biomedical research for at least another 50 years.” 
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Astma är en lungsjukdom som förekommer bland ca 10% av befolkningen. Astma har 
en komplex sjukdomsbild där både frekvensen och graden av symptom varierar över tid, 
vilket gör det svårt att ställa diagnos. Eftersom astma kännetecknas av inflammation i 
luftvägarna, och i vissa fall överkänslighet, är en av behandlingsstrategierna vid astma att 
dämpa inflammationen med hjälp av inhalerade, och/eller orala kortikosteroider. Vid en akut 
astmaattack försvåras andningen påtagligt då glattmuskulaturen drar ihop luftvägarna så att 
mindre luft kommer ned i lungorna, vilket försämrar gasutbytet och minskar syrenivån. Detta 
fenomen utgör den andra viktiga behandlingsformen vid akut luftrörsobstruktion, varvid 
luftrörsvidgande medicin ges, av typen β2-stimulerare, som relaxerar glattmuskeln.  
 
En subgrupp av astmatiker har en mer svårbehandlad astma och kräver högre doser 
eller ytterligare tilläggsbehandling. Trots ibland höga doser av kortikosteroider, tillsammans 
med annan tilläggsbehandling, saknar dessa patienter en fungerande kontroll på sina 
symptom och upplever en försämrad livskvalitet. Dessa patienter uppsöker oftare akut 
sjukhusvård. På grund av de många olika symptom som astmatiker uppvisar är det idag ännu 
oklart vilka molekylära mekanismer som kan tänkas ligga bakom varje enskilt fall. Det finns 
också en stor okunskap kring vad som molekylärt skiljer en patient med svårbehandlad astma 
från en annan. Förutom att lungfunktionen är påtagligt sämre vet man att komplexa 
inflammatoriska processer i luftvägarna är viktiga bakomliggande faktorer. Följaktligen finns 
ett stort behov av att bättre kunna diversifiera och diagnosticera astmatiker utifrån nya 
molekylära mätvariabler och med hjälp av nya metoder. 
 
En del inflammatoriska processer kan idag bara delvis förklaras av att ett förhöjt antal 
immunförsvarsceller, så som mastceller, eosinofiler och neutrofiler, som infiltrerar 
luftvägarna, eller att de cellerna utsätts för en ökad stimulering och därmed aktivering. Vid 
dessa olika aktiveringar frisätts potenta inflammatoriska signaler (mediatorer) så som 
histamin eller fettsyramolekylerna prostaglandiner och cysteinyl-leuktotriener (CysLT) vilka 
orsakar både inflammation i, och kontraktion av, luftvägarna. En central fråga i dessa 
processer är; vilka celler och signaler är det som initierar och reglerar inflammation, samt 
vilka har en direkt, eller indirekt, påverkan på luftrörskontraktion?  
 
I denna avhandling har arbetet fokuserat på att utveckla känsliga metoder för att mäta 
ett stort antal inflammatoriska signaler som frisätts från immunologiska och strukturella 
celler med hjälp av vätskekromatografi kopplat till mass-spektrometri (LC-MS). I det första 
(I) delarbetet utvecklades en metod för att mäta halten av den totala histaminfrisättningen 
indirekt, via den metabolite som histamine bryts ned till. Metoden kunde användas för att 
påvisa frånvaro av anafylaktiska reaktioner i kliniska studier på människa och samtidigt 
påvisa en högre histaminfrisättning vid systemisk mastcellsaktivering.  
 
I det andra (II) delarbetet utvecklades en metod för att kunna mäta 130 
fettsyramolekyler. Analysmetoden kunde identifiera en frisättning av 57, respektive 42, olika 
ω3- och ω6-fettsyrametaboliter från isolerad human (samt marsvin) lungvävnad efter 
allergisk stimulering. Anti-inflammatorisk behandling med COX och FLAP/5-LOX 
hämmare reducerade nivån av fettsyror producerade från dessa två enzymer och påverkade 
glattmuskeltonus. Kombinerad blockering av de två enzymerna reducerade nivåerna av 
utsöndrade pro-inflammatoriska fettsyror och reducerade glattmuskeltonus med ca 40 %.  
 
I det tredje (III) delarbetet etablerades en astmamodell i mus, där humant kvalster 
initierade eosinofil inflammation och hyper-reaktivitet i luftvägarna. En förhöjd 
koncentration av flertalet lipoxygenasfettsyror med både pro- och anti-inflammatoriska 
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egenskaper påvisades, dock utan förändring av de basalt höga nivåerna av CysLTs, vilket 
indikerar en annan fysiologisk roll för CysLTs i mus än i människa. 
 
I delarbete IV analyserades urinprover från svårbehandlade astmatiker i en stor 
Europeisk studie (U-BIOPRED) som syftade till att hitta subgrupper av astmatiker som 
kunde grupperas utifrån ett molekylärt perspektiv. Patientprofiler baserat på 11 pro-
inflammatoriska eicosanoider utsöndrade i urinen användes för klusteranalys där 5 kliniskt 
relevanta subgrupper kunde identifieras med olika lungfunktion, könsfördelning, eosinofil 
infiltration, CRP koncentration samt självuppskattad symtomkontroll och livskvalitet.  
 
Sammanfattningsvis redovisar avhandlingens resultat en metod för att mäta 
histaminfrisättningen i samband med mastcellsaktivering i kliniska studier med hög 
tillförlitlighet. Resultaten visar också hur ett stort antal ω3- och ω6-fettsyrametaboliter 
medierar kontraktion av glattmuskelvävnad samt inflammation i luftvägarna. Därutöver 
kunde en pro-inflammatorisk fettsyrametabolit-profil i urinen identifiera olika molekylära 
subgrupper bland astmatiker som också påvisade ett unikt kliniskt uttryck.  
 
Slutligen, bioanalytiska mätmetoder för bestämning av inflammatoriska mediatorers 
förekomst i biologiska system möjliggör identifiering av biologiska mekanismer i 
astmamodeller samt identifiering av nya molekylära subgrupper av astmatiker som har ett 
unikt kliniskt relevant uttryck. 
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